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6ZUSAMMENFASSUNG
Die Alzheimer’sche Erkrankung (AD) ist gekennzeichnet durch zwei wesentliche
histopathologische Merkmale, extrazelluläre aus fibrillärem Aβ-Peptid bestehenden Amyloid
Plaques und intrazelluläre Neurofibrillenbündel (NFT), welche aus hyperphosphoryliertem Tau-
Protein bestehen. Bei der mit AD verwandten neurodegenerativen Erkrankung namens
Frontotemporale Demenz mit Parkinsonismus gekoppelt mit Chromosom 17 (FTDP-17) finden
sich viele NFT ohne eine gleichzeitige Anhäufung von Plaques. Transgene Mäuse, welche das
Tau-Protein mit der Mutation P301L überexprimieren, sind ein Modell für die Taupathologie in
vivo. Diese Mäuse zeigen sowohl eine Anhäufung von hyper-phosphoryliertem Tau-Protein als
auch eine NFT-Bildung, ähnlich wie bei den humanen Krankheitsbildern AD und FTDP-17.
In unserem Labor wurde eine Proteomik-Arbeitsstation eingerichtet, um die Konsequenzen der
Taupathologie in diesen Mäusen zu untersuchen. Sowohl die sequentielle Extraktion als auch die
zweidimensionale Gelelektrophorese wurden für unsere Untersuchungen am Maushirn optimiert.
Die Analyse der P301L Tau-transgenen und Wildtyp-Kontrollhirne zeigte drei prinzipielle
Kategorien differentiell regulierter Proteine als Folge der P301L Tau-Expression auf: Proteine
mit einer Rolle im Stoffwechsel wie beispielsweise Komponenten der mitochondriellen
Atmungskette, Proteine im Zusammenhang mit oxidativem Stress und Funktionen in der
Reaktive Sauerstoff-Spezies (ROS) Detoxifikation sowie synaptische Proteine. Es ist bedeutsam,
dass die Reduktion der Mengen an mitochondrialem Komplex V in den P301L Tau-transgenen
Mäusen - wie in der Proteomanalyse aufgezeigt - in humanen P301L FTDP-17 Gehirnen bestätigt
werden konnte. Eine eingehende funktionelle Analyse zeigte eine mitochondriale Dysfunktion in
P301L Tau-transgenen Mäusen zusammen mit einer reduzierten Aktivität der NADH-Ubiquinon-
Oxidoreduktase und, als Funktion des Alters, eine reduzierte mitochondriale Atmung und ATP
Synthese. Die mitochondriale Dysfunktion war assoziiert mit erhöhten Mengen an ROS in alten
transgenen Mäusen. Die verstärkte Taupathologie in alten homozygoten P301L Tau-transgenen
Mäusen zeigte modifizierte Mengen an Lipidperoxidation und die Hochregulation antioxidanter
Enzyme als Antwort auf den oxidativen Stress auf. Ausserdem zeigten die P301L Tau-
Mitochondrien eine erhöhte Vulnerabilität nach Behandlung mit Aβ, was auf eine synergistische
Wirkung von Tau und Aβ im Hinblick auf die mitochondriale Pathologie hinweist.
Zusammengefasst schliessen wir aus unseren Untersuchungen, dass die durch Tau bewirkte
7Pathologie eine mitochondriale und mit oxidativem Stress zusammenhängende ist, und sich
möglicherweise von der durch das Aβ-Peptid ausgelösten unterscheidet.
Zusätzlich hat unsere Arbeitsgruppe für AD ein Tier- und ein zelluläres Modell entwickelt,
das sowohl die Tau- als auch die Aβ-Pathologie einschliesst. Im zellulären Modell werden P301L
Tau überexprimierende Neuroblastomzellen mit oder ohne Aβ-Peptid behandelt und im
Mausmodell werden P301L Tau-transgene Mäuse intrazerebral  mit Aβ-Peptid injiziert. Beide
Modelle wurden proteomisch untersucht und spezifische Modifikationen konnten als Folge der
Aβ-Behandlung gefunden werden.
Schliesslich haben wir das mit Streptogramin reprimierbare PipOFF Genregulations-system
in der Maus evaluiert. In der Abwesenheit von Streotograminen wird PIT exprimiert und bindet
an seinen PPIR Ziel-Promoter, was schliesslich die Transkription eines Reportergens aktiviert. Es
wurden EF1α-PIT und PPIR8-YFP doppel-transgene Mäuse hergestellt, aber es gelang uns nicht,
die Expression von PIT bzw YFP nachzuweisen. Wir modifizierten den die PIT-Expression
regulierenden Promoter und die Reportergene in CMV/β-Aktin-PIT und PPIR8-LacZ, konnten
aber auch dadurch nicht PIT bzw LacZ Expression in den Mäusen nachweisen. Wir schliessen
aus unseren Untersuchungen, dass sich das PipOFF-System in seiner gegenwärtigen Form nicht
für eine regulierte Genexpression im Mausmodell eignet.
8SUMMARY
Alzheimer’s disease (AD) is characterised by two major histopathological hallmarks,
extracellular plaques of fibrillar β-amyloid peptides and intracellular neurofibrillary tangles
(NFT) composed of hyperphosphorylated tau protein. Mutations in tau have been identified in a
related neurodegenerative disorder called frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17) with NFT formation in the absence of plaque formation. Transgenic
mice overexpressing the P301L mutant human tau protein model tau pathology in vivo. These
mice show an accumulation of hyperphosphorylated tau and NFT formation similar to those in
FTDP-17 and AD. A proteomics working station was established in the laboratory to analyse the
consequences of tau pathology in these mice. A sequential extraction and two-dimensional
electrophoresis related methods were optimised for the study of the mouse brains. Analysis of
P301L tau transgenic and wild-type control mouse brains revealed three principal categories of
proteins differentially regulated by P301L tau expression: metabolism related proteins including
mitochondrial respiratory chain complex components, oxidative stress related enzymes
implicated in reactive oxygen species (ROS) detoxification and synaptic related proteins.
Significantly, the reduction in mitochondrial complex V levels in the P301L tau mice shown
using proteomics was also confirmed as decreased in human P301L FTDP-17 brains. Functional
analysis demonstrated a mitochondrial dysfunction in P301L tau mice together with reduced
NADH-ubiquinone oxidoreductase activity and, with age, impaired mitochondrial respiration and
ATP synthesis. Mitochondrial dysfunction was associated with higher levels of reactive oxygen
species in aged transgenic mice. Increased tau pathology as in aged homozygous P301L tau mice
revealed modified lipid peroxidation levels and the up-regulation of antioxidant enzymes in
response to oxidative stress. Furthermore, P301L tau mitochondria displayed increased
vulnerability towards β-amyloid peptide insult, suggesting a synergistic action of tau and β-
amyloid peptide pathology on the mitochondria. Taken together, we conclude that tau pathology
involves a mitochondrial and oxidative stress disorder possibly distinct from that caused by β-
amyloid peptide.
In addition our group has generated a cellular and mouse model for AD which incorporates
both the β-amyloid and tau pathology. In the cellular model, P301L tau overexpressing
neuroblastoma cells were treated with or without β-amyloid peptide and in the mouse model,
P301L tau transgenic mice were intracranially injected with β-amyloid peptide. Proteomic
9analysis of both models was carried out and we detected specific modifications caused by β-
amyloid peptide treatment.
Finally we evaluated the streptogramin-repressible gene regulation system, PipOFF, in the
mouse model. In the absence of streptogramins, PIT is expressed, binds to its target PPIR promoter
and activates transcription of the reporter gene. EF1α-PIT and PPIR8-YFP double transgenic
mice were generated but we could not detect the presence of PIT or YFP. We modified the
promoter controlling PIT expression and the reporter gene to CMV/β-actin-PIT and PPIR8-LacZ.
However we could still not detect PIT or LacZ expression in these mice either. Therefore we
conclude that the PipOFF system is not suitable in its present form, to regulate gene expression in
the mouse model.
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1 INTRODUCTION
1.1 General background on Alzheimer’s disease
1.1.1 Alzheimer's Disease - A Major Health Problem
The sporadic form of Alzheimer's disease (AD) is the most common neurodegenerative disorder
among people over 65. From this age on, its prevalence doubles every 5 years and reaches about
30% of the population aged 85. Since this age group is the most rapidly increasing part of the
population in most industrialised countries, the impact of the disease on society becomes
increasingly important. The annual cost of care for a patient with moderate AD is estimated to be
around $30,000. AD not only affects patients but also presents a heavy physical and
psychological burden to their relatives who take care of them for most of the time while
observing the constant, irreversible aggravation of symptoms, until hospitalisation becomes
inevitable.
1.1.2 Clinical symptoms and cognitive tests
AD is characterised by the progressive loss of memory. Patients have more and more difficulty in
remembering names of common objects and familiar persons (agnosy), fail to carry out simple
tasks (apraxy), develop dysfunctional speech (aphasy) and eventually lose their complete
reasoning ability. The progress of the disease is correlated with abnormal behaviour, personality
changes and often with depressions. Finally patients become bedridden, completely dependent on
caretakers and develop opportunistic diseases. Most AD patients die from pneumonia. The
impact of AD has become even more evident since an established network of collaborations has
produced a standardised diagnosis of dementia (DSM IV, APA 1996), preclinical and clinical AD
(criteria of the NINCDS-ADRDA, (McKhann et al., 1984)), and the associated histopathology
(CERAD, (Mirra et al., 1994)). The aforementioned criteria allow a distinction between
"possible", "probable" or "certain" AD. Assessing the cognitive abilities in patients requires a
constant follow-up, because not the absolute level of cognitive performance, but its constant pace
of decline is indicative for AD. Cognitive tests like the Mini-Mental State exam or the Blessed
Dementia Scale are available to monitor the development of the patient's cognitive abilities and to
distinguish it from normal age-related decline. These tests are usually supported by the patient's
history, interviews with relatives and neuropsychological exercises. However, the error rate of
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"possible" or "probable" AD diagnosis in the best specialised medical centres is estimated to be
10-20%.
1.1.3 Neurodegeneration and molecular markers of Alzheimer’s disease
Alzheimer's disease is characterised by an increasing shrinkage (atrophy) of the brain. Positron
emission tomography (PET) can be used to find zones of neuronal death by monitoring the
metabolisation of radioactively marked glucose in the neurones. Another imaging technique,
magnetic resonance imaging (MRI), becomes increasingly important for measuring the
hippocampal volume and establishing an early AD diagnosis in patients with memory
impairment.
However, only after the patient has deceased will the autopsy of the brain provide the definite
histopathological evidence of the two molecular hallmarks of AD and a confirmation of the
diagnosis. The final stage of AD is characterised by the massive deposition of extracellular
neuritic plaques and intracellular neurofibrillary tangles (NFT). Neuritic plaques consist mainly
of amyloid deposits of A peptide, an extracellular proteolytic fragment of the transmembrane
amyloid precursor protein (APP)(review in (Selkoe, 1998)). NFT are proteinaceous aggregates
consisting mainly of paired helical filaments (PHF), a fibrillary polymer of the microtubule-
associated protein tau. Apart from these two unconditional signs associated with AD, Lewy
bodies and cerebrovascular amyloid can also be found.
1.2 General review on ß-amyloid pathology
1.2.1 β-Amyloid generation
In the AD brain, β-amyloid is deposited around meningeal and cerebral vessels, and in the grey
matter as β-amyloid plaques (reviewed in (Gotz et al., 2004a)). The major proteinaceous
component of these deposits is a 40-42 amino acid aggregated polypeptide termed Aβ (Aβ40 and
Aβ42), which is derived by proteolysis from the larger amyloid precursor protein, APP (Fig. 1)
(Glenner and Wong, 1984; Masters et al., 1985).
APP can be proteolytically cleaved by the membrane-associated α-secretase, which cleaves APP
within the Aβ domain. This pathway is non-amyloidogenic, as this cleavage precludes the
formation of Aβ. Alternatively, cleavage may occur in the amyloidogenic, endosomal-lysosomal
pathway, first by β-secretase and then by γ-secretase, which together generates the highly
fibrillogenic Aβ peptide. β-secretase activity has been attributed to a single protein, BACE,
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whereas γ-secretase activity was shown to depend on the presence of a total of four components:
presenilin, nicastrin, APH-1 and PEN-2 (Edbauer et al., 2003; Vassar et al., 1999).
1.2.2 β-Amyloid function and toxicity
The exact physiological function of Aβ remains unclear. It has been proposed that Aβ might act
as a physiological regulator of ion channel function in neurones, based on studies using
exogenously added Aβ peptides and neuronal primary cultures (Ramsden et al., 2002; Ramsden
et al., 2001). Furthermore non-fibrillary Aβ peptides have been demonstrated to block α7-
containing nicotinic receptors on rat hippocampal neurones in culture. Recently neuronal activity
has been shown to modulate the formation and secretion of Aβ peptides in hippocampal slice
neurones that overexpress APP (Kamenetz et al., 2003). Indeed increased neuronal activity
causes increased Aβ secretion which in turn down-regulates excitatory synaptic transmission.
Furthermore this study reveals that Aβ production impairs long-term potentiation (LTP).
Therefore Aβ could function as a synaptic transmission and plasticity regulator.
On the other hand, numerous toxic functions have been imputed to Aβ (review (Small et al.,
2001). Aβ has been shown, among other, to increase ER stress (Nakagawa et al., 2000), induce
apoptosis (Loo et al., 1993), increase reactive oxygen species (ROS) (Behl et al., 1994), inhibit
Figure 1.: Aβ generation from APP
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ATP levels through inhibition of cytochrome c oxidase activity (Keil et al., 2004; Parker et al.,
1994) and to mediate neurotoxicity by interacting with APP (Lorenzo et al., 2000).
1.2.3 Genetic involvement of amyloid precursor protein in Alzheimer’s disease
In the complex etiology of AD, in addition to environmental conditions, genetic factors play a
major role. Twin studies support the notion that 70-80% of the risk to develop AD is determined
by genetic factors (Gatz et al., 1997). Early-onset familial forms of AD (FAD) make up 1% of the
total number of AD cases (Delacourte et al., 2002). These forms of AD are characterised by
specific mutations, in the APP gene itself, and in the presenilin 1 (PS1) and presenilin 2 (PS2)
genes. Mutations in the APP gene are estimated to account for up to 5% of FAD, the most well-
known being the “Swedish mutation” consisting of a double base pair substitution
K670D/M671L (Mullan et al., 1992) and the “London mutation” consisting of the mutation
V717I (Goate et al., 1991). Until today, a total of 16 pathogenic mutations has been identified in
the APP gene (Finckh et al., 2005).
1.2.4 Amyloid precursor protein transgenic mouse models
The first APP transgenic animals to show extensive AD-like neuropathology, expressed high
levels of the disease-linked V717F mutant form of APP, under control of the platelet-derived
growth factor (PDGF) mini-promoter (Games et al., 1995; Gotz et al., 2004b). These PDAPP
mice showed many of the pathological features of AD, including extensive deposition of
extracellular amyloid plaques, astrocytosis and neuritic dystrophy. Moreover, the β-amyloid load
in the hippocampus increased as a function of age. Morris water maze testing showed memory
impairment. A second transgenic model by Hsiao et al. expressed the APP swedish mutation
inserted into a hamster prion protein (PrP) cosmid vector (Hsiao et al., 1996). The resulting
Tg2576 line developed numerous β-amyloid plaques that could be stained with the Congo red
dye. Learning was assessed in the Y-maze, a spatial alternation task, and in the Morris water
maze. At nine months of age and older, impairment in learning and memory became apparent in
these transgenic mice. Since many other groups have generated APP transgenic mouse models.
Furthermore Aβ induced pathology can be enhanced by co-expressing both the APP swedish
mutant and the presenilin M146L PS1 mutant (Holcomb et al., 1998).
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1.2.5 Anti-β-amyloid vaccination trials in humans
Currently, there are no cures for AD. Available drugs only alleviate the symptoms but are
ineffective against cognitive decline. As transgenic animal models provided evidence that both
active and passive Aβ immunisation can reduce cognitive dysfunction in APP transgenic mouse
models without any side effects, an immunisation trial was initiated in humans (review (Gotz et
al., 2004b)).
Phase I clinical trials were initiated with the AN-1792 vaccine, a pre-aggregated synthetic Aβ42
preparation, and the adjuvant QS-21 (Schenk, 2002). It could be shown that approximately 25%
of the patients produced Aβ-specific antibodies. In October 2001, a phase IIa clinical trial was
started and patients were randomised to receive AN1792/QS-21 or placebo (Orgogozo et al.,
2003). However, the dosing was prematurely halted in January 2002 when four patients who had
received the AN-1792/QS-21 vaccine developed signs of subacute meningoencephalitis (Check,
2002; Senior, 2002).
Among a cohort of 30 patients from one of the centres, 24 patients were shown to have developed
specific antibodies against Aβ, which did not cross-react with human full-length APP. These
antisera stained Aβ plaques in brain slices from APP transgenic mice and post-mortem brain
sections from patients with AD (Hock et al., 2002). Among the 24 patients, the specific immune
reaction against Aβ was still stable after one year. Moreover, this immune reaction showed a
significant correlation with slowed cognitive decline. These beneficial clinical effects could also
be demonstrated in two of three patients who had experienced immunisation-related aseptic
meningoencephalitis (Hock et al., 2003). Together, these results indicate that vaccination against
Aβ might be a potential treatment for AD, provided that a safe treatment modality can be
introduced. It is important to note that immunisation against Aβ does not seem to remove
neurofibrillary pathology as shown in post-mortem studies of three patients having received the
AN-1792 vaccine (Ferrer et al., 2004; Masliah et al., 2005; Nicoll et al., 2003).
1.3 General review on tau pathology
1.3.1 Molecular function of tau protein
Tau is the major microtubule-associated protein in axons and plays a role in neurite outgrowth,
axonal stability and transport functions in the nervous system. It belongs to the family of
microtubule-binding proteins that also comprises its close relatives, MAP2a, MAP2b (expressed
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in dendrites only, with the much shorter foetal isoform MAP2c) and MAP4 (only expressed in
peripheral tissue). These proteins range from 42kDa to 280kDa and share the common features of
3-5 C-terminal microtubule-binding repeat domains and an N-terminal projection domain.
The tau gene is present in humans in a single copy spanning 100kb at 17q21 and contains 16
exons (Andreadis et al., 1992). It is regulated by the TATA-less type promoter often found in
housekeeping genes. Of the 16 putative exons, exons 8 is never found in any human tau mRNA
(reviewed in (Andreadis, 2005). Exon 4A is only included in tau from peripheral tissue, and
exons -1 and 14 are transcribed but never translated. Foetal tau [2-,3-,10-] is the only transcript
during early brain development and contains the exons 1, 4, 5, 7, 9, 11, 12 and 13. In adult brain,
the additional exon cassettes 2, 3, and 10 can be spliced in, exon 3 never being present without
exon 2. Alternative splicing therefore leads to six different tau translation products ([2-,3-,10-];
[2+,3-,10-]; [2+,3+,10-]; [2-,3-,10+]; [2+,3-,10+]; [2+,3+,10+]). Exons 9, 11, 12 and the
alternatively spliced cassette 10 code the four microtubule-binding repeats. This alternative
splicing is developmentally regulated and different neuronal subpopulations in cortical layers
have different sets of tau isoforms.
One of the best studied roles of tau is its interaction with tubulin through three to four conserved
microtubule binding repeats located in the C-terminal half of the protein. Tau shows non-
saturable, biphasic binding behaviour to tubulin in vitro, and a higher affinity is found with the
four-repeat isoform containing an additional binding site (Ackmann et al., 2000). The N-terminal
projection domain of tau is highly acidic. Its length is determined by alternative splicing of
cassettes 2 and 3 and may be responsible for the spacing between microtubules. The projection
domain is thought to interact with other cytoskeletal proteins and the plasma membrane to confer
stability to the axons. Tau also seems to play a significant role in cellular transport. Indeed
overexpressed tau bound to microtubules inhibits anterograde kinesin-dependent transport of
mitochondria and vesicles along microtubules (Ebneth et al., 1998; Mandelkow et al., 2003;
Stamer et al., 2002).
1.3.2 Normal tau phosphorylation and abnormal phosphorylation linked to
Alzheimer’s disease
Physiological phosphorylation of tau is thought to regulate its microtubule binding proprieties.
The potential tau phosphorylation sites can be separated into two categories: the Ser-Pro (S-P) or
Thr-Pro (T-P) motifs, and the non-S/T-P motifs as for example, KXGS. The S/T-P motifs are
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phosphorylated by proline-directed kinases, for example, MAPK, GSK3 and cyclin-dependent
kinases like cdc2 and cdk5. The non S/T-P motifs have been found to be potentially
phosphorylated by MARK, PKA, CaMK II and casein kinase II. Tau phosphorylation is an active
process, as well as being developmentally regulated. Indeed tau from fetal brain is
phosphorylated at more sites than tau from adult brain, implying selective dephosphorylation of
the shortest isoform during brain maturation (Goedert et al., 1995).
In pathological circumstances, tau has been shown to be hyperphosphorylated compared to
normal adult brain tau phosphorylation. Thus, phosphorylation sites have been classified into
physiological and pathological sites. The latter include the R145d/AP422 epitope Ser-422, the
AT100 epitope Thr-212/Ser-214, and the conformation- and phosphorylation-dependent epitope
AT180/PHF-27/TG3 (Thr-231/Ser-235) (Bussiere et al., 1999; Hasegawa et al., 1996; Hoffmann
et al., 1997; Jicha et al., 1997). Hyperphosphorylation of tau reduces its binding to the
microtubules and causes its translocation from the axon to the somatodendritic domain in AD
neurones, where it forms paired helical filaments and straight filaments and finally NFT (Fig. 2).
It remains unclear whether hyperphosphorylation enhances tau assembly into PHF or not, as
contradictory studies have been published (Alonso et al., 2001; Schneider et al., 1999). Still little
Figure 2.: Neurofibrillary tangle formation
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is known about the molecular basis of tau's destructive actions. One hypothesis is that the
intracellular aggregation of tau and the formation of NFT causes cell death through gain of
function. The second or concomitant hypothesis would be that tau hyperphosphorylation and
sequestration in the cytoplasm leads to the dysregulation of the cellular microtubule dynamics
((Alonso et al., 1994), review (Feinstein and Wilson, 2005)).
1.3.3 Human tauopathies
Tau-positive filamentous lesions can be found in a wide range of neurodegenerative diseases that
are commonly regrouped as "tauopathies". With the exception of AD, A is usually absent in
most of these diseases. Accounting for the wide variety of symptoms, NFT can be found in
different parts of the brain depending on the tauopathie, can affect either neuronal cells or glial
cells or both and can occur in only certain types of neuronal cells. Often tauopathies will be
distinguished according to which isoforms accumulate to form PHF, which produces a
characteristic band pattern in gel electrophoresis. In AD, all six isoforms compose PHF. In Pick's
disease, a rare frontotemporal dementia characterised by Pick bodies in both cortical and
subcortical structures, predominantly three-repeat tau isoforms are found in the abnormal
filaments. In contrast to that, only four-repeat tau isoforms are present in NFT in neuronal and
glial cells in the cases of corticobasal degeneration (CBD), characterised by frontoparietal
atrophy, and in progressive supranuclear palsy (PSP), a late-onset atypical Parkinsonian disorder.
For some of the tauopathies, a hereditary form of the disease linked to the tau locus has been
discovered and named frontotemporal dementia with parkinsonism linked to chromosome 17
(FTDP-17) (Foster et al., 1997; Hutton et al., 1998). The characteristics of FTDP-17 diseases
depend on the nature and location of the specific mutation and sometimes give rise to the same
clinical picture as found in various sporadic tauopathies (Spillantini et al., 2000).
The FTDP-17 mutations can be classified into three groups (Table 1) (Barghorn et al., 2000;
Ingram and Spillantini, 2002). The list represented in Table 1 is not extensive. One group of
missence mutations affects the microtubule-binding function of tau and enhances its propensity to
form fibrils. A second variant encompasses mutations in exon 10 that are only found in tau
proteins with four repeats. In this group, fibrillisation is greatly increased and tau binding to
microtubules is inhibited. The third group of mutations affects the splicing of exon 10, leading to
a shift only in the ratio of four-repeat to three-repeat tau. These mutations cause only a mild
increase in the propensity to aggregation of the tau protein.
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Table 1.: Classification of FTDP-17 mutations and effect on the assembly of microtubules and
the formation of tau filaments in vitro (non-extensive list).
FTDP mutations Exon affected and effect
on isoform ratio
Inhibitory effect
on tau-promoted
microtubule
assembly
Stimulatory effect on
formation of tau
filaments
wt - 0 +
Missense mutations that alter the function of all tau isoforms
G272V 9 (normal ratio) ++ ++
V337M 12 (normal ratio) ++ ++
R406W 13 (normal ratio) + +
Missense mutations in exon 10 that alter the function of four-repeat tau isoforms only
P301L 10 (normal ratio) +++ +++
P301S 10 (normal ratio) +++ +++
Mutations that shift the four-repeat/three-repeat tau ratio
K280 10 (mostly spliced out) +++ +
L284L 10 (always included) 0 +
N279K 10 (always included) 0 +
S305N 10 (always included) 0 +
+3, +12, +13, +14,
+16, +33
intron behind exon 10
(largely included)
0 +
1.3.4 Tau transgenic mouse models
The first tau transgenic model was established in 1995 in mice by expression of the longest
human brain tau isoform under control of the hThy1 promoter (Gotz et al., 1995) (review (Gotz,
2001; Gotz et al., 2004b)). At that time, pathogenic mutations in tau had not yet been identified.
Despite the lack of NFT pathology, these mice modelled aspects of human AD, such as
somatodendritic localisation and hyperphosphorylation of tau and, therefore, represented an early
pre-NFT AD-like phenotype. The subsequent use of stronger promoters to drive transgene
expression caused a more pronounced phenotype (Ishihara et al., 1999; Probst et al., 2000;
Spittaels et al., 1999). In these mice, tau protein extracted from transgenic brain and spinal cord
became increasingly insoluble as the mice became older. Despite the decreased solubility of tau,
NFT did not form, unless the mice reached a very old age (Ishihara et al., 2001). With the
identification in 1998 of pathogenic mutations in tau in FTDP-17 (Hutton et al., 1998), several
groups achieved NFT formation both in neurones (Allen et al., 2002; Gotz et al., 2001a; Lewis et
al., 2000; Tanemura et al., 2001; Tatebayashi et al., 2002) and in glial cells of transgenic mice
(Gotz et al., 2001c; Higuchi et al., 2002). When a human tau isoform lacking the two amino-
terminal inserts, was expressed together with the P301L mutation by using the murine PrP
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promoter (Lewis et al., 2000), in a line with high expression levels, 90% of the mice developed
motor and behavioural disturbances by 10 months of age. In these mice, NFT were identified in
brain and spinal cord, and motor neurones were reduced twofold in spinal cord (Lewis et al.,
2000). The P301L mutation was also expressed in a second model using the longest human tau
isoform. In this model, the mThy1.2 promoter was chosen instead of the PrP promoter, which
may account for different expression patterns in these mice (Gotz et al., 2001a). Expression levels
of tau are high in the amygdala, hippocampus, cortex but not detectable in the cerebellum. NFT
were identified in these transgenic mice by Gallyas silver staining and thioflavin S-fluorescent
microscopy.
1.4 Amyloid cascade hypothesis: connection between tau and ß-amyloid
The pathogenic relationship of the two major lesions of AD, Aβ-plaques and NFT, and their
relative contribution to the clinical features of AD is one of the most crucial and controversial
topics in AD research. Patients bearing APP mutations develop both hallmarks, whereas tau
mutation carriers only develop NFT, providing evidence that Aβ might induce NFT formation
but not the opposite. These findings lead to the amyloid cascade hypothesis (Hardy and Higgins,
1992), which claims that (at least in familial AD) Aβ causes or enhances the NFT pathology
(review ((Gotz et al., 2004b)). Although this concept at first sight seems consistent, it is difficult
to combine it with the highly puzzling finding that plaques and NFT are neuroanatomically
separated. NFT develop in specific sites of the brain and spread in a predictable, non-random
manner across it. Six stages of disease progression based on the tau pathology have been
distinguished (Braak and Braak, 1991; Braak and Braak, 1995): the transentorhinal stages I-II
representing clinically silent cases; the limbic stages III-IV of incipient AD; and the neocortical
stages V-VI of fully developed AD. A comparative study of Aβ-associated pathology defined
five phases which differ strikingly from the NFT-stages. These findings suggest that Aβ-
deposition expands anterogradely into regions that receive neuronal projections from regions
already exhibiting Aβ (Thal et al., 2002).
Numerous correlation studies failed to demonstrate a clear relationship between the severity of
dementia and Aβ deposition in human AD brain whereas correlation between NFT numbers and
severity of dementia has been reported (Arriagada et al., 1992; Bierer et al., 1995; Crystal et al.,
1988; Nagy et al., 1996). It was shown that total NFT counts in specific brain areas such as the
entorhinal and frontal cortex, as well as neurone numbers in the CA1 region of the hippocampus
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were the best predictors of cognitive deficits in brain ageing and AD (Giannakopoulos et al.,
2003).
However, a synergistic interaction between the APP- and the tau-related pathology, despite the
different spatiotemporal distribution of plaques and NFT, has been proposed (Delacourte et al.,
1999; Delacourte et al., 2002). It was shown that whenever Aβ aggregates were detected, tau
pathology was found, at least in the entorhinal cortex. The opposite was not true because cases
were found with advanced tau pathology, with no trace of Aβ aggregates (Delacourte et al.,
2002). To address the issue of Aβ driven tau pathogenesis, our group stereotaxically injected pre-
aggregated Aβ fibrils into the somatosensory cortex and the hippocampus (CA1) of P301L tau
transgenic mice (Gotz et al., 2001b). This stereotaxic approach caused a fivefold increase in the
numbers of NFT in the amygdala of P301L mice, but not in wild-type tau transgenic or control
mice. NFT formation was associated with the pathological phosphorylation of tau at the epitopes
Thr-212/Ser-214 (AT100) and Ser-422 (pS422).
An alternative approach was pursued by intercrossing Aβ-producing APP-mutant mice (Tg2576
mice overexpressing the APP swedish mutation) with P301L tau transgenic mice (JNPL3-line)
(Lewis et al., 2001). Double transgenic mice showed a more than sevenfold increase in NFT
numbers in the olfactory bulb, the entorhinal cortex and the amygdala compared to P301L single
transgenic mice. In contrast, plaque formation was unaffected by the presence of the tau mutation
compared to APP swedish single transgenic mice. Recently, a triple transgenic model was
generated expressing mutant M146V PS1, P301L tau and the swedish APP mutation (Oddo et al.,
2003). These mice show an age-related deposition of intracellular and extracellular Aβ which
occurs before accumulation of tau protein, thus also supporting the amyloid cascade hypothesis.
Together, although these data do not prove a causal relationship between Aβ and tau pathology,
they demonstrate that Aβ can significantly accelerating the NFT formation in P301L tau mice.
Based on the in vivo data of the tau transgenic mice, our group established a cellular system using
the human SH-SY5Y neuroblastoma cell line. P301L mutant human tau was stably
overexpressed in these cells. Treatment with extracellular pre-aggregated Aβ-peptides for five
days caused the development of numerous AD-like tau filaments (Ferrari et al., 2003).
1.5 Proteomics
The significance of purely genomic approaches is undermined by a poor mRNA/protein
correlation observed in numerous studies and possibly due to mechanisms such as translational
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control, post-translational modification and regulation of protein stability (Gygi et al., 1999b).
Therefore measuring gene expression at the protein level is potentially more informative than the
corresponding measurement at the mRNA level. By definition, the proteome is the full
complement of proteins produced by a particular genome of a cell, tissue or species at a given
time. It represents a higher complexity than the transcriptome, and it displays a higher degree of
dynamics due to posttranslational modifications.
The field of proteomics has been rapidly changing over the past few years. Two-dimensional
technology has significantly improved as well as the detection limits of current mass
spectrometers. New non-gel based technologies have emerged using either a series of liquid
chromatography (LC) separations as in multidimensional protein identification technology
(MudPIT) or combining peptide labelling and LC separation such as ICAT, iTRAQ and stable
isotope labelling with amino acids in cell culture (SILAC) technologies (Gygi et al., 1999a;
Krijgsveld et al., 2003; Ross et al., 2004). Importantly, peptide labelling allows for the first time
the quantification of changes between two differently treated samples without using two-
dimensional electrophoresis (2-DE). However the implementation of non gel-based proteomics is
mainly limited by the sample complexity, which demands a significant amount of sample
fractionation, and the subsequent peptide identification by mass spectrometry (MS) normally
electrospray ionisation MS, which is very time consuming. The latter requires the availability of
considerable machine time which is generally not available in shared resource environments such
as those in functional genomic centres. Therefore 2-DE remains the current workhorse for
statistical quantitative comparison of complex samples.
1.5.1 Two-dimensional electrophoresis
In 2-DE, proteins are first separated according to charge and then in the second dimension by
mass (Hoerndli et al., 2005) (Fig. 3). 2-DE routinely allows the detection of over 3000 proteins
per gel and as little as 1 ng per protein spot. In principal, this method is capable of resolving up to
10,000 proteins in a single gel (Klose, 1975; O'Farrell, 1975).
In the first phase of 2-DE, proteins are separated by isoelectric focusing using immobilised pH
gradients (IPG) in a thin gel strip. Proteins migrate through the IPG strip until their net charge is
neutral (the isoelectric point, pI). Different IPG strips can be used, from wide pH range and
covering many pH units which allows low resolution of a large number of proteins, to narrow pH
ranges covering just one or two pH units which allows high resolution of a small number of
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proteins (Hoving et al., 2002). Following separation in the first dimension, proteins are separated
in the orthogonal direction using electrophoresis in acrylamide gels containing sodium dodecyl
sulfate (SDS), where SDS imparts a net negative charge, allowing protein separation by
molecular weight (SDS-PAGE). Once proteins are separated, they can be visualised using a
variety of stains, such as the highly sensitive Silver staining or the less sensitive Coomassie blue
staining. Alternatives are fluorescent dyes such as the SYPRO stain which is more compatible
with protein identification by MS, since the proteins are not covalently modified by the dye.
Moreover, the signal is linear over a wide range of spot intensities, allowing a more precise
quantification (Berggren et al., 2002).
1.5.2 Mass spectrometry
MS (reviewed in (Griffin and Aebersold, 2001; Steen and Mann, 2004)) is used to identify
proteins following separation by 2-DE or LC. 15 years ago, the two major techniques were
developed: matrix-assisted laser desorption ionisation (MALDI) time-of-flight (TOF) MS, and
Figure 3.: Two-dimensional electrophoresis: From isoelectrical focusing to 2-D gels.
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electrospray ionisation (ESI) MS (Banks and Whitehouse, 1996; Fenn et al., 1989; Hillenkamp et
al., 1991; Karas and Hillenkamp, 1988). The development of these relatively non-destructive, soft
ionisation methods made it possible to convert proteins into volatile ions. Usually, for peptide
mass fingerprint (PMF) analysis, the protein to be analysed is purified, and digested
enzymatically, generally by trypsin, to cleave the protein at specific bonds giving a reproducible
pattern of digestion. For ESI-MS, the resulting peptides are injected into a reverse phase HPLC
column that is directly coupled to the mass spectrometer.
For MALDI-MS, tryptic peptides are combined with a matrix on a MALDI target and then
analysed (Fig. 4). Gaseous ions are produced by accelerating an ionised particle, in this case a
peptide, through a rarefied atmosphere and the mass-to-charge (m/z) ratio is measured by the
detector. A further analysis step can be carried out by MS/MS, where the ionised peptides are
fragmented by collision induced dissociation and the m/z of each product ion is detected,
constituting a MS/MS spectrum for each peptide. Using software packages such as Mascot or
Sequest, the MS and if available, the MS/MS fingerprints are then compared to databases
containing the theoretical mass of cleaved protein and a list of the closest matching proteins is
produced.
Figure 4.: Identification of protein spots with the MALDI-TOF/TOF MS
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1.5.3 Proteomic analysis of Alzheimer’s disease
A few studies have analysed changes in the proteome associated with the progression of
Alzheimer’s disease. However the application of proteomics to the study of human brain is
undermined by post-mortem delays (Tsuji et al., 2002). Less abundant proteins are probably the
most affected by protease activity in post-mortem delays and the post-translational modifications
such as phosphorylation are prone to dephosphorylation as phosphatases remains active post-
mortem for longer than kinases. Proteomic characterisation of AD has revealed the modification
and potential dysregulation of certain categories of proteins such as metabolic, antioxidant,
synaptic, apoptotic and anti-apoptotic, and chaperone related (review (Butterfield et al., 2003)).
Furthermore increased nitration and oxidation of certain proteins in AD have also been shown by
proteomics (Castegna et al., 2002; Castegna et al., 2003; Korolainen et al., 2002).
Until now very few proteomic studies have been carried out on AD mouse models (Tilleman et
al., 2002; Vercauteren et al., 2004), although the use of these models presents several advantages.
Indeed post-mortem delays are avoided, the pathology is greatly simplified and both Aβ and tau
pathologies can be dissociated.
1.6 PipOFF transactivation system
Transgenic mice are used in many areas of research to model diseases and evaluate the function
of specific genes. However, the classical transgenic approach involves either the expression of
the transgene throughout the life-span or the knock-out of the gene of interest. The tetracycline-
inducible gene regulation system has answered this limitation by allowing the reversible and
temporary control of gene expression. Recently, a novel system, the streptogramin-based gene
regulation system, has been established in mammalian cells in cell culture (Fussenegger et al.,
2000). This system, named Pip system, exhibits superior inducibility and background expression
properties compared to the tetracycline-based system (for review see (Fussenegger, 2001)).
Furthermore, the Pip system is compatible with the tetracycline system and both could be used in
parallel to control independently more than one gene. In view of the advantages offered by this
new system, it would be essential to investigate its application to the mouse model.
1.6.1 Pristinamycin Resistance in Streptomyces
In Streptomyces pristinaespiralis, pristinamycin production and resistance are strictly co-
regulated. Pip acts as a repressor of the pristinamycin resistance determinant (ptr) by binding to
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three dyad symmetrical sites of the PPTR promoter. Pip is released from PPTR in the presence of
streptogramins and the bacterial resistance gene is expressed (Fig. 5).
1.6.2 Pristinamycin-responsive mammalian expression system
1.6.2.1 The streptogramin-repressible gene regulation system: PipOFF
The Streptomyces regulatory elements Pip and PPTR were adapted for use in a eukaryotic context
by the construction of two chimeric determinants: The pristinamycin (PI)-inhibited transactivator
(PIT, Pip fused to the VP16 transactivation domain of Herpes simplex virus) and the PI-
responsive promoter (PPIR) (PPTR fused to the minimal TATA box-containing version of the
hCMV intermediate early minimal promoter). In the absence of streptogramins, PIT is expressed,
binds to its target PPIR promoter and activates transcription of the reporter gene. After the addition
of streptogramins such as pristinamycin, PIT dissociates from PPIR and no transcription occurs
(Fig. 5).
1.6.2.2 The streptogramin-inducible gene regulation system: PipON
The “ON” configuration was constructed to offer the advantages of gene expression after the
addition of antibiotics instead of the constitutive expression in the “OFF” configuration. The
streptogramin-induced promoter PPIRON consists of a strong constitutive viral PSV40 promoter that
harbours between its TATA box and the ATG start codon of the gene of interest, an operator
sequence consisting of a PIR3 Pip-binding module. In the absence of pristinamycin, Pip binds to
Figure 5.: Pip System. Right: Regulation of Pip binding to pristinamycin resistance gene promoter.
Left: PipOFF system using Pip fused to the transactivation domain VP16 (PIT protein).
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PIR3 and suppresses transcription while with the addition of PI, Pip is released and PPIRON-
driven expression is induced.
1.7 Objectives of the Ph. D. Project
1.7.1 What are the consequences of tau pathology alone?
Little is known about the distinct intracellular mechanisms underlying the consequences of tau
pathology. This insight could help us to understand the selective vulnerability of cells with tau
pathology and thereby the pathogenesis in AD. To examine the contribution of tau to these
neurodegenerative processes, we wanted to carry out a proteomic analysis of our P301L tau
transgenic mice. To zoom in on proteins relevant to the pathology, we sequentially extracted
whole brains from six pairs of P301L tau and wild-type (WT) mice into three fractions according
to protein solubility. Comparative analysis of 2-D gels run for each fraction revealed statistically
significant differences between P301L tau and WT mice. We characterised these differences by
functional assays.
1.7.2 How does ß-amyloid influence tau pathology?
Both Gotz et al. and Lewis et al. (Gotz et al., 2001b; Lewis et al., 2001) have demonstrated that
Aβ pathology accelerates the onset of tau pathology following the amyloid cascade hypothesis
(see 1.4). We wanted to study the molecular mechanisms behind this process using proteomics.
We analysed the action of Aβ in two models established in the laboratory. In the cell culture
model (Ferrari et al., 2003), neuroblastoma SH-SY5Y cells stably overexpressing P301L tau,
were treated for five days with either fibrillary Aβ or reverse non-fibrillary Aβ. Cells were
extracted and fractionated before being analysed by 2-D gels. In the mouse model, P301L tau
transgenic mice were intracranially injected in the hippocampal CA1 region of both hemispheres
with either fibrillar Aβ or reverse non-fibrillary Aβ. As the strongest effect of Aβ on tau
pathology was observed in the amygdala, we dissected the amygdala and analysed possible
differences between Aβ and control reverse Aβ treatment by 2-D gels.
We hope that this study will reveal categories of proteins which are up- or down-regulated by Aβ
and that could influence tau pathology.
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1.7.3 Can the PipOFF transactivation system be adapted to the mouse model?
The PipOFF system was assayed in the mouse initially by co-injecting the PIT construct under
the control of the EF1α promoter and the yellow fluorescent protein (YFP) gene under the control
of the PPIR8 promoter. The functionality and suitability of the PipOFF system was evaluated.
28
2 MATERIALS AND METHODS
2.1 Proteomics study of P301L tau mice
2.1.1 P301L tau mouse generation
2.1.1.1 Transgenic mice
The transgenic mice used in the present study express the human pathogenic mutation P301L of
tau together with the longest human brain tau isoform (htau40) under control of the neurone-
specific mThy1.2 promoter (Gotz et al., 2001a). This isoform contains exons 2 and 3 as well as
four microtubule-binding repeats (2+, 3+, 4R, human tau40). Pronuclear injections were done
into C57Bl/6 × DBA/2 F2 oocytes to obtain founder animals that were back-crossed with
C57Bl/6 mice to establish transgenic lines. In addition, homozygous P301L tau mice were
obtained and confirmed by TaqMan real-time quantitative PCR.
Different age sets of mice were used for different experimental procedures corresponding to
various stages in the development of tau pathology. P301L tau mice show tau
hyperphosphorylation already at three months (Gotz et al., 2001a). NFT formation starts at six
months of age (Gotz et al., 2001b). We used 8.5-10 month old mice for the proteomics analysis to
study the consequences of tau pathology at the beginning of NFT formation without the influence
of ageing. At a similar age i.e. 12 months old, mitochondrial membrane potential, complex I and
IV activity was determined. ATP levels, mitochondrial respiration and ROS levels were analysed
in mice at 12 and 24 months of age. 24 month old mice are expected to bear the highest levels of
tau pathology. 18 month old mice were used to determine mitochondrial numbers in neurites.
This intermediate age allows us to see the full effect of tau pathology on the mitochondrial
transport without pronounced ageing effects such as in 24 month old mice. Finally 12 and 24
month old homozygous, hemizygous and wild-type mice were tested for lipid peroxidation.
2.1.1.2 Genotyping of P301L tau mice
Mouse tail lysis
2 mm of tail were cut and incubated in a thermomixer (Vaudaux-Eppendorf AG, Schönenbuch,
Switzerland) at 1400 rpm for 30 min at 55°C in 20 µl of digestion buffer (50 mM Tris pH 8.0, 20
mM NaCl, 1 mM EDTA pH 8.0, 1% SDS) supplemented with 2 µl proteinase K (20 mg/ml).
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Proteinase K digestion was terminated through denaturation in adding 178 µl double deionised
water (ddH2O) and incubating the tail lysate at 99°C for 5 min at 600 rpm in the thermomixer.
Polymerase chain reaction (PCR)
The polymerase chain reaction technique is a method to amplify DNA sequences of interest
(Mullis, 1990), by using two specific primers which are complementary to the two strands and
define the sequence to be amplified. Three major steps are involved: First, denaturation of the
DNA to single strands at 95°C. Second, annealing of the primers to their complementary
sequence on the DNA. Optimal annealing temperatures are ~ 5 to 10°C lower than the Tm values
of the primers. The primers should be designed in such a way that an annealing temperature of 55
to 65°C is allowed. Third, elongation of the DNA strand by using a heat stable DNA polymerase
adding nucleotides (dNTPs) to the 3’-ends of the primer sequences at 72°C. By repeating these
steps several times, the DNA-sequence of interest is amplified exponentially.
Transgenic P301L tau mice were screened with oligonucleotides tau-I (5'-GGAGTTCGAAGTG
ATGGAAG-3') and tau-K (5'-GGTTTTTGCTGGAATCCTGG-3'). Briefly, 0.5 µl tail mixture
was added to PCR mix (9.5 µl H2O, 1.25 µl PCR buffer, 0.25 µl 10 mM dNTP, 0.5 µl oligo tau
I/K mixture (0.2 µM), 0.5 µl Red Taq genomic DNA polymerase (Sigma, Fluka, Buchs,
Switzerland)). Using a GeneAmp PCR system 9700 machine (Applied Biosystem, Rotkreuz,
Switzerland), the reaction was heated to 95°C for 2 min before a series of 35 cycles ( 30 sec at
94°C, 30 sec at 64°C, 1 min at 72°C), then kept at 72°C for 7 min and cooled to 4°C.
Agarose gel electrophoresis
Analysis of PCR products was carried out using agarose gel electrophoresis. PCR mix containing
the PCR products were loaded onto a 1% agarose gel in TAE buffer (40 mM Tris-acetate, 1 mM
EDTA) supplemented with ethidium bromide (final concentration of 1 µg/ml). An electrical field
is used to drag the negatively charged DNA molecules (due to their phosphate groups) through
the gel matrix. The migration rate of linear DNA depends mainly on its size and the shorter the
DNA molecule the faster it moves through the gel. DNA fragments are then visualised under UV-
light by adding ethidium bromide which intercalates between the bases of DNA. The tau PCR
yields an amplification product of 500 base pairs.
2.1.2 Brain sample preparation and fractionation
Four pairs of 8.5 month old male hemizygous P301L tau and WT control mice and two pairs of
10 month old male hemizygous P301L tau and WT control mice were sacrificed by cervical
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dislocation, brains removed at 4°C, snap-frozen in liquid nitrogen and stored at –80°C until
extraction. Brains were sequentially extracted with the ReadyPrep sequential extraction kit (Bio-
Rad, Reinach, Switzerland) according to a modified version of the manufacturer’s protocol. Only
one P301L tau and one WT each were extracted at a time. All steps were carried out at 4°C
unless otherwise specified.
Briefly, whole brains were homogenised for 5 min in 3 ml of buffer 1 (40mM Tris pH 7.4,
Complete protease inhibitor cocktail (Roche, Rotkreuz, Switzerland), 0.5 mg/ml Pefabloc
(Roche), 1 mM Na3V04, 1 mM NaF) and 200 units DNaseI in a glass-teflon potter. After 15 min
on ice, the homogenate was transferred into 2 ml Eppendorf tubes and centrifuged at 15,000 x g
for 15 min in a bench centrifuge (Centrifuge 5417C, Vaudaux-Eppendorf AG, Schönenbuch,
Switzerland). Supernatant E1 was collected for further analysis and frozen in aliquots at –80°C.
The pellet was washed twice with buffer 1 using a Pipetman P1000 (Gilson Schweiz AG,
Mettmenstetten, Switzerland) and centrifuged for 10 min at 15,000 x g. The washed pellet was
resuspended by vortexing and by using a Pipetman P1000, in 750 µl buffer 2 (8 M urea, 4%
CHAPS, 40 mM Tris, 0.2% Bio-Lyte 3/10 ampholytes (Bio-Rad, Reinach, Switzerland), 2 mM
tributylphosphine (TBP)), incubated for 10 min at room temperature (RT), transferred into
Beckmann polycarbonate centrifuge tubes and ultra-centrifuged at 57,000 x g for 30 min with an
acceleration 5, deceleration 2, in a Optima TLX ultracentrifuge using a Beckmann TLA 120.2
rotor (Beckmann, Nyon, Switzerland). Supernatant E2 located between the lipid layer surface and
the solid pellet was rapidly collected with a Pasteur pipette for further analysis and frozen in
aliquots at –80°C. The pellet was washed once with buffer 2 using a 1 ml syringe with a syringe
needle (Microlance3 ref 300900, 22 x 1, ¼”-nr.12, 0.7 mm x 30 mm, BD Bioscience, Basel,
Switzerland) and centrifuged at 57,000 x g for 30 min. The supernatant was discarded and the
pellet was resuspended using a Pipetman P1000, in buffer 3 (5 M urea, 2 M thiourea, 2%
CHAPS, 2% caprylyl sulfobetaine (SB) 3-10, 40 mM Tris, 0.2% Bio-Lyte 3/10 ampholytes, 2
mM TBP). The final supernatant E3 was collected after ultra-centrifugation at 89,000 x g for 30
min at 10°C and frozen in aliquots at –80°C.
2.1.3 Protein concentration determination
Protein concentrations of cell or tissue extracts were measured as described by Lowry et al.
(Lowry et al., 1951) using the Bio-Rad DC Protein Assay Kit (Bio-Rad, Reinach, Switzerland).
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Proteins react with an alkaline copper tartrate solution and reduce the folin reagent. The reduced
folin species have a characteristic blue colour with an absorption maximum of 750 nm.
2.1.4 Isoelectrical focusing
Isoelectrical focusing (IEF) was carried out using the PROTEAN IEF Cell (Bio-Rad, Reinach,
Switzerland). Six P301L tau transgenic and six WT samples were focused simultaneously to
avoid variations between IEF runs. Each fraction from the sequential extraction (40 µg E1, 50 µg
E2 or 60 µl E3) was mixed by vortex in rehydration buffer (8.5 M urea, 4% CHAPS, 0.5%
pharmalytes pH 3-10 (Amersham, Otelfingen, Switzerland) and 1.2% DeStreak reagent
(Amersham, Otelfingen, Switzerland)). Samples in rehydration buffer were incubated at RT for
30 min and then centrifuged for 15 min at 21,000 x g in a refrigerated bench centrifuge
(Centrifuge 5417R, Vaudaux-Eppendorf AG, Schönenbuch, Switzerland) at respectively 4°C for
fractions E1 and E2 and at RT for fraction E3. Samples were then loaded on 17 cm IPG strips
(pH 3-10, Bio-Rad) in a rehydration tray. After passive rehydration for 15 h at 20°C, the IPG
strips were transferred into a IEF focusing tray and isoelectrically focused following a stepwise
increase in voltage from 150 to 10,000 V, finishing with 60,000 Vh (Table 2.). IPG strips were
then kept at –80°C until further use.
Table 2.: IEF program using the PROTEAN IEF Cell for sequential extracted brain samples
for 2-D gel analysis.
Step Voltage Voltage slope Time
1 150V linear 30min
2 300V linear 1h
3 500V linear 1h
4 1000V linear 1h
5 10,000V linear 1h30
6 10,000V rapid 60,000Vh
Prior to SDS-PAGE, the IPG strips were equilibrated in 2% DTT, 6 M urea, 2% SDS, 0.05 M
Tris pH 8.8, 20% glycerol for 30 min and then again in the same buffer with 2.5% iodoacetamide
instead of DTT for another 30 min.
For MS analysis, 150 µg E1, 150 µg E2 and 180 µl E3, respectively, were loaded on 24 cm IPG
strips (pH 3-10) and isoelectrically focused following a stepwise increase in voltage from 150 to
10,000 V, finishing with 75,000 Vh (Table 3.).
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Table 3.: IEF program using the PROTEAN IEF Cell for sequential extracted brain samples
for MS analysis.
Step Voltage Voltage slope Time
1 150V linear 30min
2 300V linear 1h
3 500V linear 1h
4 1000V linear 1h
5 5000V linear 1h30
6 5000V rapid 30min
7 10,000V linear 2h
8 10,000V rapid 75,000Vh
2.1.5 Two-dimensional electrophoresis
SDS-polyacrylamide gels were prepared twelve at a time in a PROTEAN plus Multi-casting
chamber (Bio-Rad, Reinach, Switzerland). PROTEAN plus hinged spacer plates (26.8 x 22.5 (W
x L) cm) were used to cast 25 x 20.5 (W x L) cm gels of 1 mm in thickness. After acrylamide
degassing, a 12% acrylamide solution was prepared in gel buffer (0.375 mM Tris, pH 8.8, 5%
glycerol, 1% SDS). Immediately before gel casting, 0.05% APS and 0.05% TEMED were added
to induce polymerisation. Gels were overlaid with 1 ml 50% isopropanol per gel. Gels were left
to polymerise for at least one hour at RT.
Equilibrated IPG strips are dipped twice in ddH2O and loaded onto the gels. Strips are fixed on
top of the gels using 0.5% agarose in running buffer (0.025 M Tris, 0.2 M glycine, 0.1% SDS).
Second dimension separation was performed in the PROTEAN Plus Dodeca cell electrophoresis
system (Bio-Rad, Reinach, Switzerland) filled with 25 litres running buffer. The buffer was
constantly cooled to 10°C using a K20 refrigerated circulator bath (Thermo Haake, Bio-Rad,
Reinach, Switzerland) and gels were run at 200 V constant and limited to 500 mA with a
electrophoresis power supply (Consort E865, Witec AG, Littau, Switzerland). All gels of the six
P301L tau transgenic and six WT samples from one fraction were run at the same time.
2.1.6 Two-dimensional gel staining
Silver staining allows the detection of most proteins on polyacrylamide gels. The gel is
impregnated with soluble silver ions and developed by treatment with formaldehyde, which
reduces silver ions to form an insoluble brown precipitate of metallic silver. This reduction is
promoted by proteins. Gels for the Proteomweaver comparison study were stained by Silver
staining using a modified version of Blum’s Silver staining method (Rabilloud et al., 1988). All
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steps were performed on a shaker. Briefly, 2-D gels were removed from gel plates, placed in
large plastic boxes (two per box) and fixed overnight in 500 ml 40% ethanol, 10% acetic acid.
They were then sequentially washed twice in 30% ethanol and once in ddH2O for 20 min. Gels
were sensitised in 0.02% sodium thiosulfate (Na2S2O3) for 1 min and washed 3 x 20 sec in
ddH2O. Gels were then incubated in ice-cold 0.1% silver nitrate (AgNO3) for 20 min at 4°C and
washed again 3 x 20 sec in ddH2O. The gels were developed in 3% sodium carbonate (Na2CO3)
and 0.05% formalin. As soon as the developer solution became turbid, it was renewed. When the
staining was judged sufficient, the reaction was terminated in 1% glycine for 30 min. Finally, the
gel was washed 3 x 10 min and stored in ddH2O at 4°C. Silver stained gels were scanned using an
Epson expression 1680 Pro scanner (Epson, Data Quest AG, Dietikon, Switzerland) in greyscale
with a resolution of 300 dpi and 8 bits/channel.
For MS analysis, gels were stained with Sypro Ruby (Molecular Probes, Invitrogen, Basel,
Switzerland) following manufacturer’s instructions. Briefly, gels were fixed twice in 10%
methanol, 7% acetic acid for 30 min. Gels were then stained overnight in Sypro Ruby (500 ml per
gel) in the dark. Gels were washed twice in 10% methanol, 7% acetic acid for 30 min and stored
in ddH2O at 4°C. Sypro Ruby stained gels were scanned using the fluorescent scanner, Typhoon
9400 PhosphorImager (Amersham, Otelfingen, Switzerland) with an excitation wavelength of
488 nm and an emission wavelength of 610 nm. Gels were scanned with a pixel size of 100
microns.
2.1.7 Two-dimensional gel analysis
Six P301L tau transgenic and six WT 2-D silver stained gels were compared simultaneously with
the Proteomweaver imaging software Version 2.1 (Definiens, Munich, Germany). In a first step,
the software detects all spots and then performs a matching of every gel with every gel. This
means that the spots of each gel are matched with each similar spot in every other gel, creating a
group of “superspots”. The software then normalises all gels and runs statistics to compare the 2-
D spot patterns of every transgenic gel of one fraction with the 2-D spot patterns of every WT gel
of the same fraction.
For the statistical analysis, we took only spots present in all 12 gels and with a relative intensity
average over 0.05. The spots were manually edited and bad matches were removed. Spots were
considered as differentially regulated between P301L tau and WT control samples, if they were
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up- or down-regulated by at least 1.5 fold and statistically significant with Student’s t-test (p <
0.05).
2.1.8 Spot excision
For spot excision, we used 2-D gels loaded with higher amounts of protein and stained with
Sypro Ruby which does not affect MS detection. As Sypro Ruby is a fluorescent dye, spots were
excised with the GelPix protein spot excision system (Genetix, Hampshire, UK). Briefly the gel
was laid on a glass plate, inserted into the apparatus chamber (humidity > 60%) and scanned.
Proteomweaver was used to detect the spots and the spots to be excised, were manually selected.
The excision parameters were 2 mm pin diameter, 275 µl aspiration volume, 375 µl dispension
volume and 525 orbit diameter. Spots were excised and placed in a 96 well plate (round bottom
wells).
2.1.9 Trypsin digestion of excised spots
Spots were prepared for in-gel trypsin digestion. All steps were carried out in a sterile clean
environment and at RT unless otherwise indicated. Briefly, the excised spots in a 96 well plate
were washed twice with ddH2O and then once with 50 mM NH4HCO3/30% ACN for 5 min at
37°C. The solution was removed and residual liquid was evaporated for 10 min at 60°C. The
spots were then dehydrated with 80% ACN for 10 min, the solution was removed and residual
liquid was evaporated for 10 min at 60°C. Digestion was carried out with 30 ng trypsin per spot
in digestion buffer (10 mM Tris pH 8.3, 2 mM CaCl2). Gel pieces were first transferred into 0.5
ml Eppendorfs and 4 µl of trypsin solution was added for 5 min. After rehydration of the gel
pieces, an additional 5 µl digestion buffer was added. Digestion was carried out for 3 h at 37°C.
Digested gel spots were then sonicated for 5 min in a sonication bath (Transsonic 420, Omnilab
AG, Mettmenstetten, Switzerland) and frozen at –80°C.
2.1.10 MALDI-TOF/TOF mass spectrometric analysis of digested spots
0.01% TFA (final concentration) was added to the digested gel pieces. After 5 min sonication, the
tryptic digests were desalted and concentrated using µ-C18 ZipTips (Millipore, Volketswil,
Switzerland). The bound peptides were eluted directly onto the MALDI target with 0.8 µl of α-
cyano-4-hydroxycinnamic acid matrix 5 mg/ml in 65% ACN, 35% ddH2O containing 0.1% TFA.
Digests were analysed by matrix-assisted laser desorption ionisation tandem time-of-flight mass
spectrometry (MALDI-TOF/TOF) using a 4700 Proteomics Analyzer MALDI TOF/TOF mass
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spectrometer (Applied Biosystems, Foster City, CA, U. S. A.). One mass spectrum and up to five
tandem mass spectra of all precursor ions with a minimum signal-to-noise of 80 were recorded
for each sample spot. Autoproteolytic fragments of trypsin were used as internal calibrants in the
MS mode. The mass and tandem mass spectra were analysed using Mascot (Matrix Science,
London, UK, available at http://www.matrixscience.com) as the search engine. A combined MS
and MS/MS search with a peptide tolerance of 25 ppm and an MS/MS tolerance of 0.2 Da was
carried out against the UniProt complete mouse proteome database (available at
ftp://ftp.ebi.ac.uk/pub/databases/integr8). Protein identification was considered significant if the
Mascot score was higher than the probability p < 0.05 of a random match.
2.2 Proteomics study of P301L tau expressing SH-SY5Y cells treated with ß-
amyloid
2.2.1 Aβ preparation
Aβ1-42 and reverse Aβ42-1 peptides (Bachem, Bubendorf, Switzerland) were reconstituted in PBS
to a concentration of 1.1 mM in a sterile environment and frozen at –80°C in aliquots. Before the
experiment, aliquots were diluted to 220 M in PBS and shaken at 1000 rpm for 24 h at 37°C in
an Eppendorf thermomixer (Vaudaux-Eppendorf AG, Schönenbuch, Switzerland) to allow
aggregation. These fibril preparations contain a mixture of species such as Aβ-monomers and
oligomers but also SDS-stable oligomers (Hartley et al., 1999). The Aβ fibrillary preparation is
diluted 1:22 in cell culture growth medium to a final concentration of 10 µM.
2.2.2 Cell culture
P301L tau stable transfected SH-SY5Y neuroblastoma cells (DSMZ, Braunschweig, Germany;
DSMZ No: ACC 209) were cultivated at 37°C/5% CO2/95% humidity in growth medium
(Dulbecco’s modified Eagle’s medium F-12 (DMEM F-12) supplemented with 2 mM L-
glutamine, 1% penicillin/streptomycin, 10% fetal calf serum (FCS), 5% horse serum (HS)) and
125 µg/ml gentamycin G418 (GIBCO, Basel, Switzerland). Confluent cells were washed with
PBS, trypsinized with trypsin/EDTA and passaged by splitting into half. For storage, cells were
dissociated with trypsin/EDTA (Invitrogen, Basel, Switzerland), resuspended in medium and
pelleted by centrifugation at 1000 x g for 5 min. Then the cells were resuspended in growth
medium supplemented with 10% DMSO and 10% FCS and stored in liquid nitrogen. For Aβ
treatment, batches of human P301L tau stable transfected SH-SY5Y neuroblastoma cells (DSMZ,
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Braunschweig, Germany; DSMZ No: ACC 209) from the same passage number were frozen.
Thawed cells separated from freezing medium by centrifugation, were grown in growth medium
and 125 µg/ml gentamycin G418 (GIBCO, Basel, Switzerland) for two weeks before Aβ
treatment.
For Aβ treatment, cells were plated out into 10 cm Petri dishes at a confluence of 5.5 x 105 cells
in 10 ml growth medium. 18 h afterwards, medium was removed and 5.5 ml of fresh growth
medium was added together with preaggregated Aβ42 (final concentration, 10 µM; Bachem,
Bubendorf, Switzerland) or PBS. Treated cells were incubated for 5 days without changing the
medium before being collected.
2.2.3 Sample preparation and fractionation
All steps were carried out at 4°C unless otherwise indicated.
Cells in 10 cm Petri dishes were washed twice in ice-cold PBS and collected with a rubber
scrapper in 70 µl Tris buffer (50 mM Tris pH 7.4, Complete protease inhibitor cocktail (Roche,
Rotkreuz, Switzerland), 0.5 mg/ml Pefabloc (Roche)). Samples were stored at –80°C until
extraction.
For extraction, cells collected from two plates were pooled together and the total volume was
estimated. Samples were supplemented with 5 mM DTT, Complete protease inhibitor cocktail
(Roche, Rotkreuz, Switzerland) 1x and phosphatase inhibitors (1 mM Na3V04, 1 mM NaF, 1 µM
okadaic acid). DNA was digested with the addition of 200 units DNaseI. Cells were homogenised
in a 1 ml glass-teflon potter for 4 min and incubated for 15 min. Cell lysates were centrifuged for
20 min at 21,000 x g in a refrigerated bench centrifuge (Centrifuge 5417R, Vaudaux-Eppendorf
AG, Schönenbuch, Switzerland). The supernatant (S1) containing soluble proteins was collected
and frozen in aliquots at –80°C until further use. The pellet was washed in 150 µl Tris buffer
supplemented with protease and phosphatase inhibitors but without DNaseI. Resuspension of the
pellet was carried out first with a Pipetman P200 and then a 1 ml syringe with a syringe needle
(Microlance3 ref300900, 22x1, ¼”-nr.12, 0.7mmx30mm, BD Bioscience, Basel, Switzerland).
Resuspended pellet was centrifuged at 4°C for 20 min at 21,000 x g and the wash supernatant
was discarded. The pellet was resuspended in 100 µl IEF rehydration buffer (8.5 M urea, 4%
CHAPS, 0.5% pharmalytes pH 3-10 (Amersham, Otelfingen, Switzerland)) with first a Pipetman
P200 and then a 1 ml syringe with a syringe needle (Microlance3 ref300900, 22 x 1, ¼”-nr.12,
0.7mm x 30mm, BD Bioscience, Basel, Switzerland). The resuspended pellet was incubated for
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10 min at RT before being centrifuged at 22°C for 20 min at 21,000 x g. The resulting
supernatant (S2) containing less soluble proteins was collected and frozen in aliquots at –80°C
until further use.
2.2.4 Isoelectrical focusing
S1 and S2 cell fractions were isoelectrically focused on 24 cm IPG strips (pH 3-10). Five
replicate supernatant S1 samples treated with Aβ and five treated with reverse Aβ were focused
simultaneously. Six replicate supernatant S2 samples treated with Aβ and six treated with reverse
Aβ were also isoelectrically focused together.
Briefly respectively 100 µg S1 and 67 µl S2 were added to IEF rehydration buffer (8.5 M urea,
4% CHAPS, 0.5% pharmalytes pH 3-10 (Amersham, Otelfingen, Switzerland) and 1.2%
DeStreak reagent (Amersham, Otelfingen, Switzerland)). Samples in rehydration buffer were
incubated at RT for 30 min and then centrifuged for 15 min at 21,000 x g in a refrigerated bench
centrifuge (Centrifuge 5417R, Vaudaux-Eppendorf AG, Schönenbuch, Switzerland) at
respectively 4°C for fractions S1 and at 22°C for fractions S2. Passive rehydration and
isoelectrical focusing was carried out as described in 2.1.4 and Table 3.
2.2.5 Two-dimensional gel analysis
IPG strips containing focused S1 or S2 fractions were laid on the top of 12% acrylamide SDS-
PAGE gels and separated according to molecular weight in the PROTEAN Plus Dodeca cell
electrophoresis system (Bio-Rad, Reinach, Switzerland) as described in 2.1.5. All samples from
one same fraction were separated in one same run.
Gels were stained with Sypro Ruby following the protocol described in 2.1.6. and differences
between Aβ and reverse Aβ treatment in S1 and S2 fractions were identified by Proteomweaver
(2.1.7.). For the statistical analysis, we took only spots present in all gels and we did not set a
relative intensity average limit. Spots were considered as differentially regulated between Aβ and
reverse Aβ treated samples, if they were up- or down-regulated by at least 1.5 fold and
statistically significant with Student’s t-test (p < 0.05).
2.2.6 MALDI-TOF/TOF mass spectrometric analysis
Differentially regulated spots were excised directly from the gels that were used to perform the
gel comparison (as described in 2.1.8). Spots were digested in 20 ng trypsin and analysed by
MALDI-TOF/TOF as described respectively in 2.1.9 and 2.1.10.
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2.3 Proteomics study of amygdalae from P301L tau mice injected with ß-amyloid
2.3.1 Aβ preparation
Aβ1-42 and reverse Aβ42-1 (Bachem, Bubendorf, Switzerland) were reconstituted in PBS to a
concentration of 1.1 mM in a sterile environment and frozen at –80°C in aliquots. Before the
experiment, aliquots were diluted to 250 M in PBS and shaken at 1000 rpm for 84 hours at 37°C
in an Eppendorf thermomixer (Vaudaux-Eppendorf AG, Schönenbuch, Switzerland) to allow for
aggregation.
2.3.2 Stereotaxic injection of β-amyloid
For stereotaxic injection, we chose 5.5 month old P301L tau hemizygote female mice which do
not present NFT at this age and show in general, less pathology variability than male mice.
Starting without NFT pathology should allow us to observe a clearer difference when the Aβ
treatment induces NFT formation. Female mice were injected one week before the operation with
5 units PMS (Folligon, Veterinaria AG, Zürich, Switzerland) to synchronise hormonal cycles.
Seven female P301L tau positive mice were injected with Aβ and seven with reverse Aβ.
Mice were first anaesthetised with a mixture of 0.1 ml/10 g Fentanyl (50 g/ml) (Sintenyl,
Sintetica, Mendrisio, Switzerland), Midazolam (5 mg/ml) (Dormicum, Roche, Reinach,
Switzerland), Medetomidin (1 mg/kg) (Domitor, Pfizer, Dr. El Gräub AG, Bern, Switzerland) in
NaCl 0.9%.
Figure 6.: Stereotaxic injection of Aβ
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Mice were then placed in a Stoelting stereotaxic instrument (Stoelting, Illinois, USA) (Fig. 6),
and an incision was made along the midline of the head to expose the skull. The co-ordinates for
deposition of Aβ were determined according to Bregma co-ordinates, in order to inject into the
CA1 region of the hippocampus, in both hemispheres. The calvarium was perforated with a drill
(Fine Science Tools, Aichele Medico AG, Aesch BL, Switzerland) at the positions: caudal -1.9
mm, lateral -1.2 mm and caudal -1.9 mm, lateral +1.2 mm. A 10 l Hamilton syringe was slowly
inserted 2.4 mm into the cortex. After 2 min, a total volume of 1.5 l Aβ1-42 or reverse Aβ42-1 was
injected with an injection speed of 0.15 l/min using a mini pump. The needle was kept in the
injection site for another 2 min before slowly being withdrawn.
After the operation, the mice were given 0.1 ml/10 g antidote (Naloxon (0.4 mg/ml) (Narcan,
Bristol-Myers Squibb, Baar, Swizerland), Flumazenil (0.1 mg/ml) (Anexate, Roche, Reinach,
Switzerland), Atipamezol (5 mg/ml) (Antisedan, Pfizer, Dr. El Gräub AG, Bern, Swizerland) in
NaCl 0.9%) and kept on a heating pad for 3 h.
2.3.3 Amygdala dissection
Three weeks after the Aβ or reverse Aβ injection, the mice were sacrificed by cervical
dislocation. The brain was rapidly removed and washed with ice-cold PBS. The cerebellum was
removed and then the brain was cut in half between the hippocampus and the amygdala. The
hippocampal part was immersed in 4% PFA and further used for immunohistochemistry to
determine the site of injection. The part containing the amygdala was cut into coronal slices using
a tissue chopper (Bachofer, Reutlinger, Germany) and the amygdalae were dissected under a light
microscope. Dissected amygdalae were snap-frozen in liquid nitrogen and stored at –80°C.
2.3.4 Amygdala sample preparation
Amygdalae were extracted in 200 l IEF rehydration buffer (8.5 M urea, 4% CHAPS, 0.5%
pharmalytes pH 3-10 (Amersham, Otelfingen, Switzerland). The amygdalae were first dissolved
using a Pipetman P200 and then sonicated for 3 min in a sonication bath (Transsonic 420,
Omnilab AG, Mettmenstetten, Switzerland). Homogenates were centrifuged at 89,000 x g for 30
min at 20°C in a Optima TLX ultracentrifuge using a Beckmann TLA 120.2 rotor (Beckmann,
Nyon, Switzerland). The supernatant was collected and aliquots were frozen at –80°C.
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2.3.5 Isoelectrical focusing
40 l amygdala homogenate supernatant was mixed with IEF rehydration buffer (8.5 M urea, 4%
CHAPS, 0.5% pharmalytes pH 5-8 (Amersham, Otelfingen, Switzerland), 0.25% pharmalytes pH
8-10.5) and 1.2% DeStreak reagent (Amersham, Otelfingen, Switzerland)). Samples in
rehydration buffer were incubated at RT for 30 min and then centrifuged for 15 min at 21,000 x g
in a refrigerated bench centrifuge (Centrifuge 5417R, Vaudaux-Eppendorf AG, Schönenbuch,
Switzerland) at 22°C. Samples were then loaded onto 24 cm IPG strips pH 5-8 (Bio-Rad,
Reinach, Switzerland). Amygdala samples from five Aβ and five reverse Aβ injected mice were
run together following the IEF program detailed in Table 3.
2.3.6 Two-dimensional gel analysis
Electrophoresis and gel analysis were carried out as described in 2.2.5.
2.3.7 MALDI-TOF/TOF mass spectrometric analysis
Differentially regulated spots were excised directly from the gels that were used to perform the
gel comparison (as described in 2.1.8). Spots were digested with 20 ng trypsin and analysed by
MALDI-TOF/TOF as described respectively in 2.1.9 and 2.1.10.
2.4 Methods for candidate verification
2.4.1 Gel electrophoresis
The proteins denatured and negatively charged by SDS are separated on 12% SDS-PAGE gels.
For more than 10 samples, large gels (W x L, 16 x 20 cm) were run in the PROTEAN II xi
apparatus (Bio-Rad, Reinach, Switzerland) and otherwise small gels were used (Mini-
PROTEAN, Bio-Rad, Reinach, Switzerland). Gels were cast with two layers, the resolving layer
(12% acrylamide solution in 0.375 mM Tris, pH 8.8, 1% SDS) and the stacking layer (5%
acrylamide solution in 0.12 M Tris pH 6.8, 0.1% SDS). Immediately before gel casting, 0.05%
APS and 0.05% TEMED were added to induce polymerisation. Samples were mixed with loading
buffer (33% glycerol, 6.6% SDS, 0.33 M DTT, bromophenol blue, final concentration) and
boiled before loading onto the gel. Electrophoresis was carried out at 45 mA with the voltage
limited to 250 V.
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2.4.2 Western blotting
This method combines very high sensitivity and specific protein visualisation by the use of
antibodies. The proteins charged negatively by SDS are transferred towards the positive pole onto
a nitrocellulose membrane. This is then probed with a specific primary antibody and followed by
a secondary antibody recognising the primary antibody and coupled to HRP (horseradish
peroxidase). The luminol-based substrate in the ECL reagent is oxidised by the peroxidase and
emits light captured on to the photographic film, revealing the exact position of the specific
protein.
Unless otherwise indicated all incubations were carried out for 1h at RT and the blots washed 3 x
10 min in TBS (0.01 M Tris, 0.15 M NaCl, pH 7.5). The SDS-PAGE gel was laid on to a sheet of
nitrocellulose (Hybond-C, Amersham Biosciences, Otelfingen, Switzerland) soaked in transfer
buffer (0.025 M Tris, 0.2 M glycine, 20% methanol, pH 8.3 (NaOH)). Together they were
sandwiched between one layer of Whatman filter paper and foam, inserted into a transfer cell
(Amersham Biosciences, Otelfingen, Switzerland) filled with transfer buffer. Blotting was carried
out either overnight at 45 mA or for 3 h at 150 mA. General protein levels transferred onto the
blot were thereafter determined with the reversible Ponceau S stain, which was washed off in
TBS. The blot was then incubated 1 h in blocking buffer (4% milk powder in TBS). After a
washing step of 15 min in TBS, the blot was probed with the primary antibody for 1 h at RT or
overnight at 4°C. Unbound primary antibodies were removed by washing 3 x 5 min in TBS
before the blot was re-probed for 1 h at RT with the appropriate secondary antibody conjugated
to HRP (Amersham Biosciences, Otelfingen, Switzerland). Finally after 3 x 5 min washing in
TBS, the blot was developed with ECL (Amersham Biosciences, Otelfingen, Switzerland),
following manufacturer’s instructions and exposed to a film (X-OMAT LS, Kodak/Sigma,
Buchs, Switzerland).
Evaluation of complex V levels in human brains (in collaboration with Dr. Rizzu, Amsterdam)
Homogenates from temporal cortices of 2 controls and 4 P301L FTDP-17 patients were prepared
in 150 mM Tris (pH 6.8), 2.5% SDS, 8 M urea, 20% glycerol, 10% β-mercaptoethanol and 0.1%
bromophenol blue and subjected to Western blotting using standard methods. 2.5 µl total brain
lysate were loaded. The blots were developed with antibodies directed against the complex V
component ATP synthase chain D (Molecular Probes, Invitrogen, Basel, Switzerland, 0.2 µg/ml),
and against porin for normalisation (Molecular Probes, Invitrogen, Basel, Switzerland, 0.2
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µg/ml). As secondary antibody, a goat-anti-mouse IgG (Amersham, 1:5000) was used. Non
overexposed films were used to quantify the bands with the software Image J (available from
NIH, http://rsb.info.nih.gov/ij/). Complex V levels were expressed as a percentage of porin
levels.
Samples used (as loaded) were (1) control brain, 73 year old female, (2) control brain, 72 year old
male, (3) P301L brain, 64 year old female, (4) P301L brain, 52 year old male, (5) P301L brain,
66 year old female and (6) P301L brain, 60 year old male. Three other control samples were used
(data not shown) specifically control temporal cortex from 78 year old female, 82 year old female
and 78 year old male brains.
2.4.3 Immunohistochemistry
2.4.3.1 Tissue preparation
Mice were perfused transcardially under deep anesthesia with a mixture of 2% xylazine and 10%
ketamine (15 µl/g body weight). For that, the thorax was opened to expose the heart and major
vessels. A cannula was inserted through the left ventricle into the ascending aorta. Right away,
the right atrium was punctured with a scissors, to allow the efflux of return circulation. To
remove the blood, mice were initially perfused with PBS (1x) for 5 min until the liver turned
beige-yellow, followed by fixation with 4% paraformaldehyde in PBS for 15 min. Brains were
then removed, postfixed in the same fixative solution overnight and washed 3x with PBS over 24
h. The brains were then dehydrated respectively in ethanol 70%, 96%, 100% for three hours in
each solution and changed every hour. Brains were left overnight in xylol and immersed in liquid
paraffin at 60°C for 5 h. Finally the brains were cooled down in paraffin blocks.
2.4.3.2 Immunostaining of paraffin sections
5 m thin paraffin coronal sections were cut for immunohistochemistry and brain areas were
mapped based on the mouse atlas by Paxinos (Paxinos, 1997). To allow antibodies to penetrate
fixed tissue embedded in paraffin, sections were dewaxed at 60°C for 2 h, then in xylol and
rehydrated in a descending series of ethanol (5 min each, 3 x xylol baths, 2 x ethanol 100%, 96%
ethanol, 70% ethanol, 2 x ddH2O). Sections were then permeabilised with methanol for 10 min at
-20 °C. To increase immunoreactivity, depending on the type of antigen, sections were micro-
wave treated in citrate-buffer pH 5.8 at 70°C for 15 minutes. Sections were blocked in PBS pH
7.4 containing 4% BSA and 6% goat serum. Sections were incubated with the primary antibody
43
overnight at 4°C or for 1 h at RT. Sections were washed three times with PBS and incubated with
the secondary antibody for 1 h at RT. The immunostained sections were washed again 3 x and
then mounted with the anti-fading reagent (Mowiol), and analysed by conventional
immunofluorescence.
2.4.4 Crude synaptosome preparation
All steps were performed at 4°C unless otherwise specified.
Five transgene and five WT 12 month old mice were sacrificed by cervical dislocation, the brain
was removed and the cerebellum discarded. Brains were washed with ice-cold PBS and weighed.
Homogenisation was carried out in 10 volumes per brain weight synaptosome homogenisation
buffer (0.32 M sucrose, 4 mM HEPES pH 7.4, Complete protease inhibitor cocktail (Roche,
Rotkreuz, Switzerland)) at 900 rpm in a glass-teflon potter. Homogenates were centrifuged for 10
min at 1000 x g in a refrigerated bench centrifuge (Centrifuge 5417R, Vaudaux-Eppendorf AG,
Schönenbuch, Switzerland). The supernatant was centrifuged in a second step at 17,000 x g for
15 min. The resulting pellet was resuspended in 1 ml synaptosome homogenisation buffer and
further centrifuged at 17,000 x g for 15 min. The washed pellet was then resuspended in 10 mM
HEPES, 100 mM NaCl, 1 mM MgCl2, 0.5 mM CaCl2, Complete protease inhibitor cocktail
(Roche, Rotkreuz, Switzerland), and frozen at –80°C in aliquots. This resuspension contains a
mixture of synaptosomes, endoplasmic reticulum and mitochondria.
2.4.5 Evaluation of lipid peroxidation levels and antioxidant enzyme activity
Preparation of brain hemispheres to determine lipid peroxidation and antioxidant enzyme
activities. (in collaboration with Dr. Eckert, Frankfurt/Basel)
Mice were anaesthetised and blood was removed by transcardial perfusion with PBS pH 7.4. One
hemisphere was minced in 1 ml of cold 20 mM TBS with ten strokes in a Potter homogeniser at
1200 rpm (the other hemisphere was fixed in PFA). An aliquot of this homogenate was diluted
1:1 with TBS, centrifuged at 3,000  g for 10 min at 4°C and supernatants were collected and
stored at -80°C for lipid peroxidation assays. The remaining homogenate was centrifuged at
8,500  g for 10 min at 4°C, and supernatants were collected and stored at -80°C until antioxidant
enzyme activity determination.
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Assay of lipid peroxidation products:
The lipid peroxidation product malondialdehyde (MDA) was determined by a photometrical
method using the Lipid Peroxidation Assay Kit (Calbiochem) (Esterbauer and Cheeseman, 1990).
The colorimetric reaction is a condensation of the aldehyde with 1-methyl-2-phenylindole
yielding a chromophore with an absorption maximum at 586 nm. Basal levels of MDA were
assayed after incubation of samples for 30 min at 37°C, and stimulated MDA levels were
determined under the same conditions in the presence of 50 µM FeCl3 in the sample homogenate.
Cu/Zn-SOD activity:
Cu/Zn-SOD (EC 1.15.1.1) activity was measured with the Superoxide Dismutase Assay Kit
(Calbiochem) (Nebot et al., 1993). To remove interfering substances and rule out Mn-SOD
activity, Cu/Zn-SOD enzyme activity was assayed after an extraction procedure with chloroform
and ethanol according to the supplier’s manual. SOD activity was calculated based on the Vs/Vc
ratio of the autoxidation rates of the chromophore BXT-01050 measured at 37°C in the presence
(Vs) and absence (Vc) of sample. The chromophore was measured in a Genesys 5 photometer
(Spectronic Instruments, Rochester, USA) at 525 nm. One Cu/Zn-SOD activity unit is defined as
the activity that doubles the auto-oxidation background (Vs/Vc = 2).
GPx activity:
GPx (cytosolic GPx, EC 1.11.1.9) activity was measured using the Cellular Glutathione
Peroxidase Assay Kit (Calbiochem) (Paglia and Valentine, 1967) and tert-butylhydroperoxide as
substrate. This reaction is based on the enzymatic reduction of hydroperoxide by GPx under
consumption of reduced glutathione GSH which is restored from oxidised glutathione GSSG in a
coupled enzymatic reaction by GR. GR reduces GSSG to GSH under consumption of NADPH as
reducing equivalents. The decrease in absorbance at 340 nm due to NADPH consumption was
measured in a Victor2 multiplate reader using a 355 nm filter with 40 nm bandpass. One unit of
GPx is defined as the activity that converts 2 µmol of reduced glutathione per minute at 25°C.
GR activity:
The GR (EC 1.8.1.7.) activity was determined using the Glutathione Reductase Assay Kit
(Calbiochem) (Mizuno and Ohta, 1986). The enzymatic activity was assayed photometrically by
measuring NADPH consumption during the enzymatic reaction. In the presence of GSSG and
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NADPH, GR reduces GSSG and oxidises NADPH to yield NADP resulting in a decrease of
absorbance at 340 nm, which was measured in a Victor2 plate reader. One unit of GR is defined
as the activity that reduces 1 µmol of GSSG (corresponding to 1 µmol of NADPH) per minute at
25°C.
2.4.6 Mitochondrial assays
Brain tissue preparation for mitochondrial analysis. (in collaboration with Dr. Eckert,
Frankfurt/Basel)
Mice (8 pairs of 12 month and 8 pairs of 24 month old hemizygous P301L tau and WT control
mice) were sacrificed by decapitation and brains were quickly dissected on ice (modified after
(Stoll et al., 1992)). After removing the cerebellum, one hemisphere (the other hemisphere was
directly used for preparation of isolated mitochondria) was minced into 1 ml of medium I (138
mM NaCl, 5.4 mM KCl, 0.17 mM Na2HPO4, 0.22 mM K2PO4, 5.5 mM glucose, 58.4 mM
sucrose, pH 7.35) with a scalpel and further dissociated by trituration through a nylon mesh (pore
diameter 1 mm) with a Pasteur pipette. The resulting suspension was filtered by gravity through a
fresh nylon mesh with a pore diameter of 102 µm, and the dissociated cell aggregates were
washed twice with medium II (110 mM NaCl, 5.3 mM KCl, 1.8 mM CaCl2*H2O, 1 mM
MgCl2*6 H2O, 25 mM glucose, 70 mM sucrose, 20 mM HEPES, pH 7.4) by centrifugation (400
x g for 3 min at 4°C). 100 µl of the suspension were used for protein determination. After
centrifugation, cells were resuspended in 3 ml DMEM, then aliquots of 100 µl were distributed
per well in a white 96 well plate for measurement of ATP levels and aliquots of 250 µl were
distributed per well in a 48 well plate for measurement of the mitochondrial membrane potential
and ROS levels. The latter were maintained at 37°C in a humidified atmosphere of 5% CO2/95%
air for the staining period with the appropriate dye or incubated with A for 4 hours. The
preparations of cortical cells from P301L tau transgenic mice and WT littermate controls (cross-
over design) were made within 2 hours under the same conditions and in parallel. Data are
expressed as fluorescence unit per mg/ml protein. The total protein content was determined
(Lowry et al., 1951).
Determination of the mitochondrial membrane potential m:
The membrane potential of the inner mitochondrial membrane was measured using the
Rhodamine 123 (R123) dye added to the cell culture medium at a final concentration of 0.4 µM
46
for 15 min. Cells were washed twice with HBSS (Hank’s Balanced Salt Solution, Sigma,
Germany), and fluorescence was determined with a Victor2 multiplate reader (Perkin Elmer,
Rodgau-Jügesheim, Germany) at 490 nm/535 nm (Ex/Em). Loading capacity of the dye within
the membrane decreases when the mitochondrial membrane potential declines after damage, e.g.
exposure to Aβ1-42. For the secondary insult with Aβ1-42, cells were incubated for 4 hours with 50
nmol/l pre-aggregated Aβ1-42.
To test acute and fast changes in m, the fluorescent dye Tetramethylrhodamine-ethylester
(TMRE) was used at 0.4 µM for 15 min. TMRE exhibits a characteristic increase in fluorescence
at 490 nm/590 nm (Ex/Em) after challenging mitochondria with drugs which decrease the
membrane potential. The mitochondrial membrane potential was recorded with the respiratory
inhibitors rotenone (2 µM), thenoyltrifluoroacetone (TTFA, 10 µM), antimycin (2 µM),
oligomycin (10 µM) and sodium azide (10 mM) (Collins et al., 2002; Krohn et al., 1999).
ATP levels:
ATP levels were determined with a bioluminescence assay (ViaLight HT, Cambrex Bio Science).
The enzyme luciferase is utilised which catalyses the formation of light from ATP and luciferin.
The emitted light is linearly related to the ATP concentration and is measured using a
luminometer (Crouch et al., 1993).
ROS levels:
Levels of cytosolic ROS were measured using the fluorescent probe 2’,7’-
dichlorodihydrofluorescein diacetate (H2DCF-DA) and levels of superoxide anion radical by
using dihydroethidium (DHE), respectively. Brain cells were loaded for 15 minutes with 10 µM
H2DCF-DA or 10 µM DHE. After washing twice with HBSS, formation of the fluorescent
product DCF was detected with Victor2 multiplate reader (Perkin Elmer) at 485 nm/535 nm
(Ex/Em). DCF is trapped mainly in the cytoplasm and is oxidised by several ROS, most notably
hydrogen peroxide (Kenney and Kocsis, 1998). DHE which is oxidised to the fluorescent
ethidium cation by O2.- was detected with Victor2 multiplate reader at 490 nm/590 nm (Ex/Em)
(Budd et al., 1997).
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Amount of mitochondria:
The total amount of mitochondria was measured using the cell-permeable mitochondrion-
selective dye MitoTracker Green FM (100 nM, 15 min) which is essentially nonfluorescent in
aqueous solutions and only becomes fluorescent once it accumulates in the lipid environment of
mitochondria (490 nm/516 nm Ex/Em). To determine numbers of mitochondria, in addition, four
pairs of 18 month old P301L tau transgenic and WT mice were perfused transcardially with 4%
paraformaldehyde in microtubule stabilisation buffer (65 mM PIPES, 25 mM HEPES, 10 mM
EGTA, 3 mM MgCl2, pH 6.9). 5 µm paraffin brain sections were co-immunostained with anti-
porin (A31855, Molecular Probes, Invitrogen, Basel, Switzerland; diluted 1:2000) and anti-
tubulin antibodies (YOL 1/34, Abcam Limited, Cambridge, UK; 1:600) followed by incubation
with Cy3- and Cy2-conjugated secondary antibodies (Jackson Immunoresearch, Milan Analytic,
Fribourg, Switzerland). Numbers of mitochondria in neurites of CA1 hippocampal neurones were
counted both proximal and distal to the cell body.
Preparation of isolated mitochondria:
Mice were sacrificed by decapitation and one brain hemisphere was rapidly dissected on ice and
washed in an ice-cold buffer (210 mM mannitol, 70 mM sucrose, 10 mM HEPES, 1 mM EDTA,
0.45% BSA, 0.5 mM DTT, protease inhibitor cocktail Complete tablets, Roche Diagnostics).
After removing the cerebellum, the tissue sample was homogenised in 2 ml buffer with a glass
homogeniser (10 to 15 strokes, 400 rpm) and the resulting homogenate was centrifuged at 1400 x
g for 7 min at 4°C, to remove nuclei and tissue particles. The low speed centrifugation step was
repeated once with the supernatant. Then, the supernatant fraction was centrifuged at 10,000 x g
for 5 min at 4°C to pellet mitochondria. The resulting pellet was resuspended in 1 ml ice-cold
buffer and centrifuged again at 800 x g for 3 min at 4°C. Finally, the mitochondria-enriched
supernatant was centrifuged at 10,000 x g for 5 min at 4°C to obtain a mitochondrial fraction.
This fraction was resuspended in 100 µl of ice-cold buffer and stored at 4°C until use, followed
by determination of protein content (Lowry et al., 1951).
Mitochondrial respiration:
The rate of mitochondrial respiration was monitored at 25°C using an Oxygraph-2k system
(Oroboros, Innsbruck, Austria) equipped with two chambers and DatLab software. Mitochondria
(0.5 mg) were added to 2 ml of a buffer containing 65 mM sucrose, 10 mM potassium phosphate,
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10 mM Tris-HCl, 10 mM MgSO4 and 2 mM EDTA (pH 7.0). State 4 respiration was measured
after adding 40 µl malate/glutamate (240 mM/ 280 mM; assay concentration 4.8/5.6 mM). Then,
10 µl ADP (100 mM; assay concentration 0.5 mM) were added to measure state 3 respiration.
After determining coupled respiration, 1 µl carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP, 0.1 mM; assay concentration 0.05 nM) was added to
the reaction chamber, and respiration was measured in the absence of a proton gradient. To
inhibit complex I activity, a total volume of 3 µl (2 + 1 µl) rotenone (0.1 mM; final concentration
0.15 nM) was added. Then, 10 µl succinate (1 M; final concentration 5 mM) was added and
respiration was measured. Finally, 8 µl KCN (0.5 M; assay concentration 2 nM) was added to
inhibit complex IV activity. P301L tau mice and WT mitochondria were measured in parallel
pairs using the same conditions (cross-over design).
Complex I activity:
Isolated mitochondria were solubilised in n-dodecyl β-D-maltoside (20%) (Sigma-Aldrich,
Taufkirchen, Germany). NADH: hexaammineruthenium(III)-chloride (HAR) activity was
measured at 30°C in a buffer containing 2 mM Na+/MOPS, 50 mM NaCl and 2 mM KCN (pH
7.2) using 2 mM HAR and 200µM NADH as substrates to estimate the complex I content. To
determine NADH:ubiquinone oxidoreductase activity, 100 µM n-decylubiquinone (DBQ) and
100 µM NADH were used as substrates, as described previously (Djafarzadeh et al., 2000).
Oxidation rates of NADH were recorded with a Shimadzu Multi Spec-1501 diode array
spectrophotometer (340 – 400 nm = 6.1 mM-1 cm-1). Complex I activity was normalised to the
complex I content of the mitochondrial preparation and is given as DBQ/HAR ratio.
Complex IV activity:
Cytochrome c oxidase activity was determined in intact isolated mitochondria using the
Cytochrome c Oxidase Assay Kit. The colorimetric assay is based on the observation that a
decrease in absorbance at 550 nm of ferrocytochrome c is caused by its oxidation to
ferricytochrome c by cytochrome c oxidase. The Cytochrome c Oxidase Assay was performed as
described previously (Rasmussen and Rasmussen, 2000).
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2.5 Study of tau insolubility after proteasome inhibition in P301L tau
overexpressing SH-SY5Y cells treated with ß-amyloid
We wanted to test potential consequences on tau insolubility that could be mediated by
proteasome inhibition with and without Aβ.
2.5.1 Neuroblastoma SH-SY5Y cell differentiation and Aβ treatment
To induce neuronal differentiation, P301L tau stable expressing cells were seeded on collagen
type I-coated 10 cm Petri dishes at a confluency of 8 x 105 cells per dish and sequentially treated
for 5 days with retinoic acid (20 µM; Sigma, Buchs, Switzerland) in growth medium
((Dulbecco’s modified Eagle’s medium F-12 (DMEM F-12) supplemented with 2 mM L-
glutamine, 1% penicillin/streptomycin, 10% FCS, 5% HS) and 125 µg/ml gentamycin G418
(GIBCO, Basel, Switzerland)), followed by 5 days with brain-derived neurotrophic factor
(BDNF; 50 ng/ml; Peprotech, Lucerne, Switzerland) in serum-free medium (Encinas et al.,
2000). These neuronal differentiated cells were then further cultured in serum-free medium.
Suspensions of fibrillar Aβ1-42 preparations (see 2.2.1) corresponding to 10 µM soluble peptide
were added to the cultures for five days (see 2.2.2). Once Aβ1-42 had been added to the cells, the
medium was not changed anymore.
2.5.2 Proteasome inhibition in cell culture
We used three different proteasome inhibitors in cell culture. SH-SY5Y cells were differentiated
and treated with Aβ or PBS as described in 2.5.1. Low concentrations of proteasome inhibitors
(Affiniti, Exeter, UK) were added at the same time as Aβ and again 48 h afterwards. We used
lactacystin (final concentration in cell growth medium, 1 µM) and epoxomicin (0.01 µM), both
shown to strongly inhibit chymotrypsin-like proteasome activity (Kim et al., 1999; Vigouroux et
al., 2003) and MG132 (0.005 µM), shown to inhibit all three peptidase activities of the
proteasome (Vigouroux et al., 2003). We tested the cells with PBS, Aβ, each proteasome
inhibitor or each proteasome inhibitor together with Aβ. At least two replicates for each condition
were performed.
2.5.3 Sequential extraction of insoluble tau protein
The level of insoluble tau protein was determined by sequentially extracting Aβ-treated and
reverse Aβ control cells using buffers with increasing ionic strength. All steps were carried out at
4°C unless otherwise indicated.
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Cells in 10 cm Petri dishes were washed twice in ice-cold PBS and collected with a rubber
scrapper in 100 l RAB buffer (0.1 M MES, 1 mM EGTA, 0.5 mM MgSO4, 0.75 M NaCl, 0.02
M NaF, 1 mM PMSF, 0.1 mM EDTA), supplemented with Complete EDTA-free protease
inhibitor cocktail (Roche, Basel, Switzerland) and 0.5 mg/ml Pefabloc (Roche). Cells were
homogenised on ice with a Microlance 25 GA1 tip and then incubated for 20 min, followed by
centrifugation for 20 min at 10,000 x g. The supernatant containing mostly soluble proteins was
carefully removed (RAB fraction) and the RAB-insoluble pellet was extracted in 100 l RIPA
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate,
1% NP40) with a Microlance 26 GA5/8 tip. After incubation for 20 min and centrifugation for 20
min at 10,000 x g, the supernatant containing mostly membrane proteins was recovered (RIPA
fraction). The RIPA insoluble pellet was transferred with a pipette tip to a Beckman centrifuge
tube. The pellet was extracted in 100 l 70% formic acid (FA) with a Microlance 26 GA5/8 tip
and incubated for 20 min. The FA-solution was centrifuged for 30 min at 50,000 x g in an
Optima TLX ultracentrifuge using a Beckmann TLA 120.2 rotor (Beckmann, Nyon,
Switzerland). The supernatant containing insoluble tau protein was transferred onto a Millipore
dialyze membrane (Millipore, Volketswil, Switzerland) and dialyzed against 50 mM Tris pH 7.4,
1 mM DTT, and 0.1 mM PMSF for 1 h at RT (FA fraction). All fractions were stored in aliquots
at -80°C.
Tau insolubility was evaluated by Western blotting of the FA samples probed with the human
specific tau antibody, HT7 (Innogenetics Inc, Belgium).
2.6 Study of tau phosphorylation in P301L tau mouse brains
To characterise pathological related tau phosphorylation in the P301L tau mice, we carried out a
sequential tau extraction to isolate “AD-P tau” adapted from Alonso et al. and Köpke et al.
(Alonso et al., 1994; Kopke et al., 1993).
2.6.1 Tau extraction
All steps were carried out at 4°C unless otherwise indicated.
Mice were sacrificed by cervical dislocation, the brain was removed and washed in ice-cold PBS.
The cerebellum was removed and the remaining brain was snap-frozen in liquid nitrogen.
Homogenisation was performed in 4.5 ml homogenisation buffer (20 mM Tris pH 8.0, 0.32 M
sucrose, 5 mM EGTA, 5 mM MgSO4, 5 mM DTT, Complete protease inhibitor cocktail (Roche,
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Basel, Switzerland), 50 mM NaF, 1 mM Na3V04, 1 µM Okadaic acid, 0.1 mM PMSF) in a glass-
teflon potter for 5 min. Homogenates were incubated for 10 min and centrifuged at 27,000 x g for
30 min with an acceleration 5, deceleration 2, in a Optima TLX ultracentrifuge using a Beckmann
TLA 120.2 rotor (Beckmann, Nyon, Switzerland). Supernatant was removed and ultra-
centrifuged at 200,000 x g for 1 h. The resulting pellet was resuspended in 100 µl 8 M urea with a
Pipetman P200 and incubated at RT for 1 h, before a final centrifugation at 334,000 x g for 45
min at 22°C. The supernatant obtained should contain hyperphosphorylated AD-P tau and was
stored at –80°C in aliquots until analysis.
2.6.2 Proteomics
AD-P tau fraction was mixed with IEF rehydration buffer (8.5 M urea, 4% CHAPS, 0.5%
pharmalytes pH 5-8, 0.25% pharmalytes pH 8-10.5 (Amersham, Otelfingen, Switzerland)) and
1.2% DeStreak reagent (Amersham, Otelfingen, Switzerland)). Samples in rehydration buffer
were incubated at RT for 30 min and then centrifuged for 15 min at 21,000 x g in a refrigerated
bench centrifuge (Centrifuge 5417R, Vaudaux-Eppendorf AG, Schönenbuch, Switzerland) at
22°C. The samples were then loaded onto 17 cm IPG strips pH 5-8 (Bio-Rad, Reinach,
Switzerland) and isoelectrically focused following the program detailed in Table 2. Focused IPG
strips were loaded on 10% SDS-PAGE gels and 2-D patterns were revealed by Silver staining.
We also probed for tau protein using the anti-human tau HT7 antibody by Western blotting after
transferring the 2-D gel onto a nitrocellulose membrane.
2.7 PipOFF system
2.7.1 PipOFF constructs
Original constructs were obtained from Prof. Fussenegger  (ETH, Zürich, Switzerland). All
cloning was done by Daniel Schuppli.
Two PIT constructs:
EF1α-PIT: pMF255 vector containing the EF1α promoter and PIT gene.
CMV/β-actin-PIT: PIT gene was cloned into the pCAGGS vector containig the CMV-IE
enhancer and the chicken beta-actin promoter.
Three reporter constructs:
PPIR8-YFP: YFP (from the pd2EYFP-N1 vector) was inserted into the pBP33 vector containing
the PPIR8 promoter.
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PPIR8-GFP: pMF164 containing the PPIR8 promoter and GFP gene.
PPIR8-LacZ: LacZ gene was inserted into the pBP33 vector containing the PPIR8 promoter.
2.7.2 Transgenic mouse generation
Pronuclear injections were done into C57Bl/6 × DBA/2 F2 oocytes to obtain founder animals.
We generated EF1α-PIT and PPIR8-YFP co-injected mouse founders as well as CMV/β-actin-
PIT and PPIR8-LacZ coinjected mouse founders. We also generated single transgenic EF1α-PIT;
single transgenic PPIR8-YFP and single transgenic PPIR8-GFP. Single transgenics were crossed
to generate double transgenics.
2.7.3 PCR
DNA was extracted from tail biopsies using the Genelute mammalian genomic DNA kit (Sigma,
Buchs, Switzerland). PCR was carried out using a GeneAmp PCR system 9700 machine (Applied
Biosystem, Rotkreuz, Switzerland). For EF1α-PIT, PPIR8-YFP and PPIR8-GFP PCRs, 0.5 µl tail
mixture was added to PCR mix (15.9 µl H2O, 2.05 µl PCR buffer, 0.41 µl 10 mM dNTP, 0.41 µl
oligo mixture (20 pmol/µl), 0.82 µl Red Taq genomic DNA polymerase (Sigma, Fluka, Buchs,
Switzerland)).
PIT PCR for EF1α-PIT: Screened with PIT fv (5’-CCCCACGACTCCGCCGGGTACG-3’) and
PIT rv (5’-CCTCCCACACCTCCCCCTGAACCTGA-3’). The reaction was heated to 95°C for 2
min before a series of 35 cycles (30 sec at 94°C, 30 sec at 64°C, 50 sec at 72°C), then kept at
72°C for 7 min and cooled to 4°C.
YFP PCR for PPIR8-YFP: Screened with YFP fv (5’-CATGGTGAGCAAGGGCGAGGAG-3’)
and YFP rv (5’-TGTCGCCCTCGAACTTCACCTC-3’). The reaction was heated to 95°C for 2
min before a series of 35 cycles (30 sec at 94°C, 30 sec at 56°C, 50 sec at 72°C), then kept at
72°C for 7 min and cooled to 4°C.
GFP PCR for PPIR8-GFP: Screened with OMF34 (5’-GATCGAATTCGATCCAAGCTTG
CCTCGAG-3’) and OMF37 (5’-GATCCTGCAGCCCGGGTTATTTGTAGAGCTCATC-3’).
The reaction was heated to 95°C for 2 min before a series of 35 cycles (30 sec at 94°C, 30 sec at
55°C, 1 min at 72°C), then kept at 72°C for 7 min and cooled to 4°C.
PIT PCR for CMV/β-actin-PIT: Screened with first star PIT up (5’-CCATCTCGGCCGTCTTCC
AGTTCGTCT-3’) and star PIT low (5’-ACTCGTCAATTCCAAGGGCATCGGTAAA-3’) and
in a second step, the products of the PCR were screened using PIT nestup (5’-CCATCTCGGCC
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GTCTTCCAGTTCGTCTAC-3’) and PIT nestlow (5’-AGCCGCCAGCCCCGCCTCTTC-3’).
For both reactions, 1 µl tail mixture or PCR reaction was added to PCR mix (38.5 µl H2O, 5 µl
PCR buffer, 1 µl 2 mM dNTP, 1 µl oligo mixture (20 pmol/µl), 2.5 µl Red Taq genomic DNA
polymerase (Sigma, Fluka, Buchs, Switzerland)). For the first PCR, the reaction was heated to
95°C for 2 min before a series of 35 cycles (30 sec at 94°C, 30 sec at 56°C, 1 min at 72°C), then
kept at 72°C for 7 min and cooled to 4°C. For the second PCR, the reaction was heated to 95°C
for 2 min before a series of 35 cycles (30 sec at 94°C, 30 sec at 61°C, 50 sec at 72°C), then kept
at 72°C for 7 min and cooled to 4°C.
LacZ PCR of PPIR8-LacZ: Screened with CAGGS1691-1718 (5’-GGTTATTGTGCTGTCTCA
TCATTTTGGC-3’) and lacZ322-295 (5’-TGGGATAGGTTACGTTGGTGTAGATGGG-3’).
0.5 µl tail mixture was added to PCR mix (15.5 µl H2O, 2 µl PCR buffer, 0.4 µl 10 mM dNTP,
0.8 µl oligo mixture (20 pmol/µl), 0.8 µl Red Taq genomic DNA polymerase (Sigma, Fluka,
Buchs, Switzerland)). The reaction was heated to 95°C for 2 min before a series of 35 cycles (30
sec at 94°C, 30 sec at 55°C, 50 sec at 72°C), then kept at 72°C for 7 min and cooled to 4°C.
2.7.4 Cell culture
Mouse 3T3 fibroblasts were grown as described in 2.2.2.and plated at 0.4 x 106 cells/well in 6
well plates 24 h before transfection. EF1α-PIT and PPIR8-YFP plasmids were introduced using a
gene gun (Bio-Rad, Reinach, Switzerland). After transfection, cells were treated with and without
20 µg/ml Pristinamycin (PI) from Pyostacin tablets (Aventis, Paris, France) solubilised in
DMSO. After 24 h PI treatment, the cells were observed under the fluorescence microscope.
2.7.5 Tail staining
To check for YFP expression in double transgenic EF1α-PIT and PPIR8-YFP founders, we
performed immunostaining on tail biopsies. As control, the tail from a constitutive GFP
expressing mouse was taken. Tails were embedded in paraffin, sectioned and immunostained
with the anti-GFP antibody ab290 (Abcam, Cambridge, UK) at the dilution 1:200 (as described in
2.4.3).
2.7.6 Western blotting
Organs were homogenised 5 min in a glass-teflon potter in RIPA buffer (50 mM Tris pH 8.0, 150
mM NaCl, 5 mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40) supplemented with
Complete EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland) and 0.5 mg/ml
54
Pefabloc (Roche). Homogenates were centrifuged at 21,000 x g for 10 min at 4°C and
supernatant was frozen in aliquots at –80°C. Transfected cells with both EF1α -PIT and PPIR8-
YFP plasmids were used as the positive control. 50 µg was loaded on a 12% SDS-PAGE and
subsequently blotted (as described in 2.4.2.). To detect the PIT protein, we used the antibody sc-
7545 (Santa Cruz Biotechnology, Labforce, Nunningen, Switzerland) against the VP16
transactivator domain of PIT at the dilution 1:100. To detect YFP or GFP, we used the anti-GFP
antibody ab290 (Abcam, Cambridge, UK) at the dilution 1:2000.
2.7.7 LacZ staining
2.7.7.1 LacZ staining of mouse ears
Ear punches were washed in PBS and fixed for 15 min in 0.2% glutaraldehyde in PBS. After
three time washing for 5 min in PBS, they were stained in X-gal stain (1 mg/ml X-gal, 5 mM
C6FeK3N6, 5 mM C6FeK4N6, 0.01% sodium deoxycholate, 0.02% Nonidet-P40, 2 mM MgCl2,
PBS pH 7.3) overnight at 37°C.
2.7.7.2 LacZ staining of cryostat sections
LacZ staining of cryostat sections was used to check for beta-galactosidase expression in the
LacZ ear positive mouse. The mouse was perfused with PBS, organs were removed and directly
embedded in Tissue freezing medium (Jung, Leica, Glattbrugg, Switzerland) in isopentane cooled
on dry ice. Organs were cut into 10 µm thick sections and dried. For LacZ staining, sections were
fixed in cold PBS containing 0.2% glutaraldehyde for 10 min and then washed 3 x 5 min in lacZ
wash buffer (2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% Nonidet-P40, PBS pH 7.3).
Sections were then stained in X-gal stain solution (1 mg/ml X-gal, 5 mM C6FeK3N6, 5 mM
C6FeK4N6, 0.01% sodium deoxycholate, 0.02% Nonidet-P40, 2 mM MgCl2, PBS pH 7.3)
overnight at 37°C. Finally sections were washed 3 x 5 min in PBS.
55
2.8 Antibodies used
Table 4.: Antibody list.
Antibody Specificity Source IC WB
HT7
Monoclonal phosphorylation-
independent human tau antibody,
epitope corresponding to aa 159-163
Innogenetics Inc, Belgium 1:200 1:500-1:1000
α-
Synaptophysin Polyclonal anti-synaptophysin Dako, Zug, Switzerland 1:200
α-
Synaptophysin Monoclonal anti-synaptophysin Sigma, Buchs, Switzerland 1:2000
α-Synapsin Polyclonal anti-synapsin Molecular Probes, Invitrogen,Basel, Switzerland 1:600
α-DRP Monoclonal anti- dihydropyrimidinaserelated protein
Supplied by: Maho Morishima
and Yasuo Ihara, Department of
Neuropathology, Faculty of
Medicine, University of Tokyo,
Japan
1:7000
α-CDCrel-1 Monoclonal anti-CDCrel-1 (septin 5)
Supplied by: Hansruedi Büeler,
Institute of Molecular Biology,
University of Zurich, Switzerland
1:400
α-GFP Anti green fluorescent protein, ab290 Abcam, Cambridge, UK 1:200 1:2000
α-porin Monoclonal anti-porin Molecular Probes, Invitrogen,Basel, Switzerland 1:2000 1:5000
α-complex V Monoclonal anti-OxPhos Complex V Molecular Probes, Invitrogen,Basel, Switzerland 1:5000
α-tubulin
Monoclonal anti-tubulin, epitope
corresponding to aa 414-422, YOL
1/34
Abcam Limited, Cambridge, UK 1:600
α-PIT (VP16) Anti VP16(sc-7545), epitopecorresponding to aa 456-490 of VP16
Santa Cruz Biotechnology,
Labforce, Nunningen,
Switzerland
1:100
α-GFAP Polyclonal anti-glial fibrillary acidicprotein Sigma, Buchs, Switzerland 1:100
α-actin Monoclonal anti-actin, ab6276 Abcam, Cambridge, UK 1:5000
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3 RESULTS
3.1 Proteomics optimisation for the analysis of P301L tau mouse brains
3.1.1 Optimisation of the sequential extraction for whole brain samples
Most studies published until recently have performed 2-DE analysis without carrying out any
prefractionation. However as there is no amplification method like PCR for nucleic acid, it is
essential to carry out fractionation of the sample to improve detection of less abundant proteins
especially from highly complex tissues such as brain. Indeed without prefractionation, 2-D gels
of whole brain samples contain mostly structural protein such as tubulin and actin, and metabolic
related proteins such as enolase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate
kinase, triosephosphate isomerase, phosphoglycerate mutase which form large groups of protein
spots covering up less abundant proteins. We chose to carry out a sequential extraction according
to protein solubility.
Figure 7.: Sequential extraction according to protein solubility.
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To extract mouse brain samples, we have adapted a sequential extraction established by Molloy
et al. (Molloy et al., 1998) for Escherichia coli proteins. Using this method, brain proteins were
sequentially extracted into three fractions according to their solubility, namely E1 (soluble
proteins), E2 (intermediate soluble) and E3 (less soluble) (Fig. 7). We optimised the starting
homogenisation volume by increasing it to 3 ml, which improved extraction quality.
Centrifugation steps were also optimised to improve separation especially of E2 and E3 fractions.
DNaseI was added to the homogenate to remove DNA which causes vertical streaking in 2-DE.
3.1.2 Optimisation of two-dimensional gel quality and spot resolution
3.1.2.1 Isoelectrical focusing and two-dimensional electrophoresis
The three main optimisations in isoelectrical focusing concerned the amount of sample loaded,
the IEF program and the reduction of sample oxidation. We could show that increasing the
protein load on the IPG strip did not necessarily increase the amount of spots detected on the 2-D
gel. On the contrary, decreasing the amount of proteins down to 40 µg E1, 50 µg E2 and 60 µl E3
significantly increased the number of spots distinguished on the 2-D gels. This suggests that high
amounts of certain proteins impair isoelectrical focusing. In order to improve horizontal streaking
in 2-D gel patterns, we introduced a stepwise increase in voltage during IEF (see material and
methods, 2.1.4) to enhance protein focusing and we also increased the total focusing time as
compared to most IEF programs. The most significant improvement of 2-D gel quality and spot
resolution came with the use of the Destreak reagent. Oxidation is a major problem during the
IEF runs and causes horizontal streaking. The Destreak reagent contains several reductants and
when added to the protein sample in IEF rehydration buffer, it transforms the thiol groups into
stable disulphide groups thus preventing unspecific oxidation. The use of Destreak greatly
improved the resolution and allowed us for the first time to perform gel comparison between
samples with significant matching between gels (Fig. 8).
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Minor optimisations concerned the IEF rehydration, the IPG strip size, IPG equilibration times
and gel thickness. We tried various IEF rehydration buffers, with different concentrations of urea,
with or without thiourea, with either pharmalytes from Amersham or bio-lytes from Bio-rad, with
different reductants such as TCEP or TBP. The final and optimal rehydration buffer contained 8.5
M urea, 4% CHAPS, 0.5% pharmalytes pH 3-10 and 1.2% DeStreak. In order to improve
resolution and number of spots resolved, we switched from 7 cm IPG strips to 17 cm. The IPG
strip equilibration step is an essential step needed to allow the IEF focused proteins to fully
interact with SDS and in order to reduce and alkylate sulfhydryl groups with respectively DTT
Figure 8.: Representative 2-D gels. A, Example of early gels. 80 µg of E1 (left) and E2 (right) were
loaded onto 7 cm IPG (pH 3-10) strips in rehydration buffer (8 M Urea, 2% CHAPS, 7.5 mM DTT, 0.5%
pharmalytes pH 3-10). B, Horizontal streaking and poor resolution without Destreak. 250 µg were
loaded on 17 cm IPG strips in rehydration buffer (8 M urea, 4% CHAPS, 0.5% pharmalytes pH 3-10
supplemented with 2 mM TBP). C, Representative gels with Destreak reagent, used for
Proteomweaver comparison. 40 µg E1, 50 µg E2 and 60 µl E3 were loaded in rehydration buffer (8.5 M
urea, 4% CHAPS, 0.5% pharmalytes pH 3-10 and 1.2% DeStreak reagent).
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and then iodoacetamide thus preventing their reoxidation. We optimised the equilibration
incubation times to 30 min for each step as too short or too long times diminished the quality of
the gels both in resolution and in numbers of spots observed. We also improved resolution by
decreasing the thickness of the SDS-PAGE gels from 1.5 mm to 1 mm.
3.1.2.2 Gel staining
The most important proprieties of protein detection methods are high sensitivity, high linear
dynamic range, reproducibility and compatibility with MS. We chose to use MS compatible
Silver staining which is far more sensitive than Coomassie Blue and can detect as low as 1 ng
protein/spot. However it is important to note that Silver staining has a limited dynamic range and
is rapidly saturated. We evaluated four different MS-compatible Silver staining methods to select
for the protocol with the best reproducibility and sensitivity. Silver staining kits from both Bio-
Rad (Silver Stain Plus Kit) and Amersham Biosciences (PlusOne Protein Silver Staining Kit)
lacked in sensitivity. The Silver staining protocol according to Shevchenko et al. (Shevchenko et
al., 1996) produced uneven staining. A modified version of Blum’s Silver staining was judged to
be the most reproducible and sensitive Silver staining from among those tested.
3.1.3 Two-dimensional electrophoresis gel comparison
We tested two different software to compare differences between gels. The Melanie software was
developed by the Swiss Institute of Bioinformatics and is distributed by GeneBio. This software
has the advantage that the user can modify a great number of parameters during the analysis.
However to perform a comparison between groups of samples, it is necessary to select a
reference gel for each group, to which all gels of one group will be matched and similarly a
reference gel must be chosen before matching between groups. This means that spots not present
in the reference gel will not be taken into consideration in the comparison process. After testing
the Melanie software on the E1 fractions, we tried the Proteomweaver software. This software
offers a more powerful algorithm than the Melanie software as it allows the matching of 2-D
patterns of every gel with every gel without the use of reference gels. Therefore the multi-
matching performed by Proteomweaver provides a consistent spot identification in the whole
experiment and avoids unnecessary elimination of protein spots not present in a specific gel.
Proteomweaver also provides a replicate quality test which we used to test the minimum trustable
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regulation factor that could be used for each fraction. This was less than 1.5 for gels from each
fraction.
3.1.4 Optimisation of protein identification
3.1.4.1 Trypsin digestion
We tried out various trypsin digestion protocols with Silver stained spots. We evaluated the use
of Silver destaining, protein reduction and alkylation, peptide extraction after digestion and the
amounts of trypsin needed for digestion. As several aspects of the sample preparation for trypsin
digestion and MS analysis parameters were sometimes modified in parallel, it is not always
possible to evaluate which steps brought a significant improvement or not. In general, we found
that removing silver ions by destaining with 30 mM K3(Fe(CN)6) in 100 mM Na2S2O3 for 10 min
helped protein identification. An additional protein reduction and alkylation step during spot
preparation does not improve MS analysis. Peptide extraction from gel pieces after digestion
using several acetonitrile steps, also does not help MS analysis. Overall we can conclude that it is
best to keep to a minimum the number of steps during spot preparation. Furthermore it is also
important to reduce trypsin amounts to 20-30 ng per spot, as too high levels of trypsin peptides
prevent the detection of other peptides by the MALDI MS. Analysis of both Silver stained and
Sypro Ruby stained spots revealed that Silver staining significantly impairs MS detection as
compared to Sypro Ruby. Most of the spots shown to be regulated in our samples were weakly
stained spots and the identification of these spots was only possible after Sypro Ruby staining. To
improve detection, we also increased protein load up to 150 µg on 2-D gels by employing 24 cm
IPG strips rather than 17 cm.
3.1.4.2 Mass spectrometric identification
We evaluated both ESI and MALDI-TOF MS. However we obtained very poor results with ESI
MS for digested protein spots. ESI MS analysis has also a major disadvantage compared to
MALDI-TOF MS as the analysis of one spot takes in total three hours together with a wash run,
whereas MALDI-TOF MS followed by MS/MS needs only a few minutes per spot. The accuracy
of MALDI-TOF/TOF MS was continually improved by Dr. Peter Gehrig at the FGCZ centre with
the most important improvement being the internal calibration of MS according to trypsin peptide
m/z instead of solely an external calibration.
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3.2 Proteomic analysis of P301L tau mouse brains
We performed a proteomic study to carry out an unbiased characterisation of the consequences of
the expression of the human P301L mutant tau in a transgenic mouse model (David et al., 2005).
To favour the visualisation of a relatively large proportion of different proteins on 2-D gels, the
brain proteins were sequentially extracted in three fractions according to their solubility, namely
E1 (soluble proteins), E2 (intermediate soluble) and E3 (less soluble). The proteins of each
fraction from six pairs of hemizygous P301L tau and WT control mice were first focused in 17
cm IPG strips depending on their pI and then resolved in the second dimension by their molecular
weight on SDS-PAGE gels. Silver staining revealed reproducible 2-D protein patterns for each
sequentially extracted fraction. Differences between transgenic and WT mice were highlighted by
the Proteomweaver software which normalises the overall spot intensities and then performs a
comparison of every gel with every other gel. Protein spots that differed by more than 1.5-fold
and statistically significant by Student’s t-test (p < 0.05), were considered for further
investigation. Overall, we found 15 up-regulated and 22 down-regulated protein spots in P301L
tau transgenic mice as compared to WT controls, including four up- and four down-regulated in
fraction E1, ten up- and seventeen down-regulated in fraction E2 and one up- and one down-
regulated in the last fraction E3. After trypsinization, all but three of these differentially regulated
protein spots were identified by MALDI-TOF/TOF mass spectrometry (Table 5). Several spots
contained more than one protein and some were identified as the same protein.
The greater part of the regulated spots identified are related to either metabolism and
mitochondrial respiration, oxidative stress or synapse function. In the first category, we identified
one spot as the 30 kDa subunit of the NADH-ubiquinone oxidoreductase (electron transport chain
complex I) and two spots as the ATP synthase D chain (complex V). All three spots were down-
regulated as well as the metabolic related spots, triosephosphate isomerase (TPI), a glycolytic
enzyme, and the cytoplasmic malate dehydrogenase involved in the malate-aspartate shuttle
providing a metabolic co-ordination between cytosol and mitochondria. In contrast, a spot
identified as inorganic pyrophosphatase was up-regulated. Associated with oxidative stress, spots
representing the antioxidant enzymes peroxiredoxin 6, perioredoxin 3 (thioredoxin-dependent
peroxide reductase), glutathione S-transferase (GST) P2 and Mu1, and phospholipid
hydroperoxide glutathione peroxidase (PHGPx) were all down-regulated. In the last functional
category, we found up-regulated spots related to synaptic function, such as the synaptic vesicle
associated proteins, synapsin I, CDCrel 1 and septin 11, the axonal growth related protein,
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dihydropyrimidinase related protein 2 (DRP-2) and another member of the dihydropyrimidinase
family, DRP-3. Further differentially regulated spots (Table 5) included stathmin, a microtubule
destabilising protein; MSTI1, the murine homologue of hop (heat-shock protein 70/heat-shock
protein 90 (HSP70/HSP90) organising protein); γ-SNAP, involved in vesicle trafficking; the β-
alanine oxoglutarate aminotransferase homologue, a GABA transaminase; the probable D-
tyrosyl-tRNA deacylase and the growth factor receptor-bound protein 2 (GRB2), an adapter
protein in signalling pathways. Therefore, P301L tau expression results in distinct modifications
of the brain proteome suggesting alterations in the mitochondrial electron transport chain, in
cellular antioxidant capacities and in synaptic properties.
Table 5.: Protein alterations in P301L tau mice.
Protein Accession
numbera
Fractionb Spot
number
Fold
difference
Student’s
t test
Mascot
scorec
Proteins involved in mitochondrial respiration and
metabolism:
NADH-ubiquinone oxidoreductase 30kDa subunit Q9DCT2 E2 375 -1.62 0.0089 101
ATP synthase D chain Q9DCX2 E2 455 -1.90 0.0124 134
ATP synthase D chain Q9DCX2 E2 1457 -1.66 0.0026 62
Triosephosphate isomerase P17751 E2 750 -1.79 0.0139 71
Inorganic pyrophosphatase (2010317E03Rik protein) Q9D819 E1 576 1.56 0.0007 218
Malate dehydrogenase, cytoplasmic P14152 E1 323 -1.58 0.0096 63
Proteins involved in oxidative stress:
Peroxiredoxin 6 O08709 E2 38 -1.90 0.0076 287
Thioredoxin-dependent peroxide reductase
(perioredoxin 3)
P20108 E2 978 -1.76 0.0007 91
Glutathione S-transferase P2 P19157 E2 443 -1.68 0.0104 158
Glutathione S-transferase Mu 1 P10649 E2 622 -1.61 0.0145 182
Phospholipid hydroperoxide glutathione peroxidase O70325 E1 1605 -1.57 0.0168 98
Synaptic related proteins:
Dihydropyrimidinase related protein-2 O08553 E1 311 1.50 0.0074 305
Dihydropyrimidinase related protein-2 O08553 E1 1983 1.53 0.0136 103
Dihydropyrimidinase related protein-2 O08553 E2 1853 1.62 0.0001 222
Dihydropyrimidinase related protein-2 O08553 E2 140 1.59 0.0000 133
Dihydropyrimidinase related protein-2 O08553 E2 1289 1.51 0.0001 105
Dihydropyrimidinase related protein-3 Q62188 E1 1307 1.64 0.0217 81
Synapsin I O88935 E2 1597 1.91 0.0069 172
Synapsin I O88935 E2 2160 1.83 0.0077 140
Septin 11 Q8C1B7 E2 1589 1.70 0.0152 122
Septin 5 (CDCrel-1) Q9Z2Q6 E2 2112 1.59 0.0002 341
Other proteins:
Stathmind P54227 E1 2156 -1.66 0.0081 55d
MSTI1 (stress-induced phosphoprotein 1)
Stress-induced phosphoprotein 1
Q60864
Q99L66
E2
E2
1741
1741
1.53
1.53
0.0064
0.0064
113
101
Gamma-soluble NSF attachment protein (γ-SNAP) Q9CWZ7 E3 337 -1.52 0.0048 491
Endoplasmic reticulum protein Erp29 precursor P57759 E2 778 -2.08 0.0058 134
Endoplasmic reticulum protein Erp29 precursor P57759 E2 582 -1.72 0.0112 100
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Lipoamide acyltransferase component of branched-
chain alpha-keto acid dehydrogenase complex
P53395 E2 1893 1.50 0.0126 87
Beta-alanine oxoglutarate aminotransferase homologue
(GABA transaminase)
Q8BZA3 E2 240 -1.71 0.0107 74
mus musculus adult male kidney cDNA; gene name:
ethe1, synonym: hsco
Q9DCM0 E2 782 -1.56 0.0137 71
Probable D-tyrosyl-tRNA deacylase Q9DD18 E1 251 -1.71 0.0004 131
GRB2 adapter protein Q60631 E2 1213 -1.57 0.0100 122
Lamin C and C2
Lamin A
Paraspeckle protein 1
P11516
P48678
Q8R326
E2
E2
E2
1207
1207
1207
1.86
1.86
1.86
0.0075
0.0075
0.0075
203
203
196
Myeloid leukemia factor 2 Q99KX1 E2 1609 -1.56 0.0190 83
UPF0082 Q8K0Z7 E3 178 1.58 0.0086 135
a SWISS-PROT/TrEMBL accession number.
b Sequential extraction fraction where the protein was identified.
c Mascot protein identification score is –10*Log (P) where P is the probability that the observed match is a random
event. Protein scores greater than 57 are significant (p<0.05) as based on the mouse database used here.
d This spot was independently identified twice as stathmin with a Mascot score near to significance. Tandem mass
spectra were manually validated and the identification was considered correct.
Human P301L FTDP-17 brains show decreased complex V levels. As the proteomics
comparison of the P301L tau and WT control mice revealed a significant decrease of two spots
identified as the ATP synthase D chain, we looked at complex V levels in human FTDP-17
patient brains carrying the P301L tau mutation. Four P301L FTDP-17 brain and two control brain
homogenates were examined by Western blotting (Fig. 9A).
We used the mitochondrial protein marker, porin to control for variations in mitochondrial
amounts. Normalisation of complex V levels with porin levels showed a significant decrease in
complex V levels in all P301L brain samples compared to control brains (Fig. 9B). Similar
control complex V/porin percentages were found in three other control brain samples (data not
shown). In average, we measured a 62.3% reduction of complex V levels in P301L FTDP-17
brains compared to control brains. The decreased levels of complex V in human P301L FTDP-17
brains confirms the proteomics observation made in the P301L tau transgenic mice and suggests
that the P301L mutant tau pathology causes potentially a specific mitochondrial dysfunction in
humans as well as in mice.
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3.3 Functional analysis of P301L tau mouse brains
3.3.1 Synaptic deficit
Figure 10.: Synaptophysin staining of 18 month old P301L tau transgenic and WT hippocampi.
Synaptophysin (Dako) used at 1:200 followed by Cy3 conjugated anti-rabbit. No significant
difference can be observed between synaptic staining of transgenic and WT mice.
Figure 9.: Reduced complex V levels in human P301L FTDP-17 brains. A, Western blot of
human temporal cortex brain homogenates. Complex V (ATP synthase) is recognized as
the lower band using an anti-ATP synthase D chain antibody and the mitochondrial protein
marker, porin as the upper band using an anti-porin antibody. Control brain homogenates
were loaded in lanes 1 and 2 and P301L FTDP-17 brain homogenates in lanes 3 to 6. B,
Complex V/porin percentages for control and P301L brains after Western blot band
quantification. Sample percentages are represented in the same order as on the Western
blot above.
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The proteomic data obtained from comparing P301L tau transgenic and WT mice suggest a
potential synaptic dysfunction. To evaluate this, we performed both immunostaining of coronal
brain slices with synaptophysin and synapsin and Western blotting of homogenates and crude
synaptosome preparations with synapse specific antibodies. We could not observe any significant
difference in general synapse staining as evaluated by anti-synaptophysin (Dako, Zug,
Switzerland) (Fig. 10). Immunostaining with anti-synapsin (Molecular Probes, Invitrogen, Basel,
Switzerland) did not show specific synaptic staining.
Fraction E2  P301L tau positive P301L tau negative
average SD average SD
Synapsin 1.574 0.734 1.385 0.397
CDCrel-1 0.402 0.115 0.425 0.143
Figure 11.: E2 fractions probed with synapsin and
CDCrel-1. 10 µg of E2 fractions were loaded per well.
Synapsin and CDCrel-1 bands were normalised with actin
bands. No significant differences in levels of synapsin or
CDCrel-1 can be observed between P301L tau and WT
mice.
Fraction E2  P301L tau positive P301L tau negative
average SD average SD
DRP 0.542 0.115 0.449 0.060
Synaptophysin 5.4 8.7 7.7 12.5
Figure 12.: E2 fractions probed with DRP and
Synaptophysin. 10 µg of E2 fractions were loaded per well.
DRP and synaptophysin bands were normalised with actin
bands. No significant differences in levels of DRP or
synaptophysin can be observed between P301L tau and WT
mice.
Crude synapto-  P301L tau positive P301L tau negative
some prepara- average SD average SD
tions
DRP 0.287 0.227 0.266 0.174
CDCrel-1 1.162 0.738 1.411 1.083
Figure 14.: Crude synaptosome preparations probed with
DRP and CDCrel-1. 5 µg of crude synaptosomes were
loaded per well. DRP and CDCrel-1 bands were
normalised with actin bands. No significant differences in
levels of DRP or CDCrel-1can be observed between P301L
tau and WT mice.
Crude synapto-  P301L tau positive P301L tau negative
some prepara- average SD average SD
tions
Synapsin 2.863 4.362 2.433 4.052
Synaptophysin 0.907 0.350 0.938 0.706
Figure 13.: Crude synaptosome preparations probed with
synapsin and synaptophysin. 5 µg of crude synaptosomes
were loaded per well. Synapsin and synaptophysin bands
were normalised with actin bands. No significant differences
in levels of synapsin or synaptophysin can be observed
between P301L tau and WT mice.
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To better quantify any potential synaptic deficit, we carried out Western blotting with first E2
fractions and then crude synaptosome preparations. We probed against synapsin, DRP and
CDCrel-1, all found by proteomics as up-regulated in the P301L tau mice and against
synaptophysin. After normalisation of these proteins with actin, the average intensity for both
P301L tau mouse and WT control bands was calculated. We found no statistical difference
between transgenic and WT mice, for any of these synaptic proteins (Fig. 11, 12, 13, 14).
However it is important to note that we observed a great variability in levels of all these synaptic
related proteins both in E2 fraction and in crude synaptosome preparations (see standard
deviations (SD) in Fig. 11, 12, 13, 14). Therefore these results do not preclude that a potential
synaptic dysfunction could be present.
3.3.2 Mitochondrial deficit
P301L tau mice exhibit mitochondrial respiratory defects. We examined the metabolic
capacity and function of cerebral mitochondria from P301L tau transgenic mice. Consistent with
the down-regulation of subunits of mitochondrial electron transport chain complexes I and V,
treatment with specific complex inhibitors showed a general reduction in mitochondrial
depolarisation of P301L tau brain cells compared to WT and specifically a significantly reduced
depolarisation after inhibition of complexes I and V (Fig. 15A).
Using a direct measurement of complex I activity, we observed a significant reduction of NADH-
ubiquinone oxidoreductase (NADH:DBQ) activity in mitochondria of 12 month old P301L tau
mice (Fig. 15B), whereas NADH:HAR activity (Fig. 15C) was not different indicating that
complex I content is similar in P301L tau and WT control mice. Thus, P301L tau mitochondria
present a functional defect of complex I activity with a reduction of 30.75% as revealed after
normalising complex I activity with complex I content (Fig. 15D). In contrast, complex IV
showed no differences in the cytochrome c oxidase activity between WT and P301L tau
transgenic mice (Fig. 15E).
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Figure 15.: Impaired depolarization and reduced mitochondrial complex I activity in P301L tau mice. A,
Use of specific complex inhibitors reveals a significantly reduced depolarization of mitochondria from 12
month old P301L tau mice after treatment with the complex I inhibitor rotenone (Rot) and the complex V
inhibitor oligomycin (Oligo) (*p<0.05, **p<0.01 vs. corresponding WT control mice, Student’s t-test). A
similar tendency was also found by inhibition of complex II with TTFA, complex III with antimycin (Ant) and
complex IV with NaN3. Two-way ANOVA reveals a significant effect of the transgene (p<0.01) and
individual complexes (p<0.001) with no interaction between the two parameters. B-D, Complex I activity in
cerebral mitochondria from 12 month old P301L tau mice and age-matched WT control mice. B, Reduced
NADH-ubiquinone oxidoreductase (NADH:DBQ) activity in mitochondria of P301L tau mice (*p<0.05 vs.
WT control mice, Student’s t-test). C, Unaltered NADH:HAR activity. D, Complex I activity was normalized
to the complex I content of the mitochondrial preparation and is given as DBQ/HAR ratio (*p<0.05 vs. WT
control mice, Student’s t-test). E, Unaltered complex IV activity. All values represent  S.E. from n=6-8
animals per group.
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In addition, we determined the state 3 and state 4 respiration using substrates for complex I
(glutamate/malate) (Fig. 16A, B). State 3 respiration measures the capacity of mitochondria to
metabolise oxygen and the selected substrate in the presence of a limited quantity of ADP, which
is a substrate for the ATP synthase (complex V). State 4 respiration measures respiration when all
ADP is exhausted and is associated with proton leakage across the inner mitochondrial
membrane. Therefore, it represents a “basal-coupled” rate of respiration. Whereas state 3 and
state 4 respiration remained unchanged with complex I substrates in 12 month old P301L tau
mice (Fig. 16B, upper panel), a significantly reduced state 3 respiration could be observed in 24
Figure 16.: Oxygen electrode reveals a reduction of O2 consumption of P301L tau mitochondria during aging.  A,
Representative diagrams of measurement of oxygen (O2) consumption in mitochondria from a 24 month old WT control
(upper panel) and from an age-matched P301L tau mouse (lower panel) demonstrating a decrease in the total O2
concentration with time. O2 flux and consumption by mitochondria (mito) was measured after addition of different agents
(marked by arrows): malate/glutamate (mal/glu; state 4), ADP (state 3), FCCP, rotenone (rot), succinate (suc), and KCN.
B, O2 consumption in freshly isolated cerebral mitochondria from 12 month (upper panel) and 24 month old mice (lower
panel), respectively. State 4 was measured after adding malate/glutamate. Then, ADP was added to measure state 3
respiration. After determining coupled respiration, FCCP was added and respiration was measured in the absence of a
proton gradient. To inhibit complex I activity, rotenone was added. Then, respiration was measured after adding
succinate. Finally, complex IV activity and O2 consumption was inhibited by treatment with KCN. Two-way ANOVA
reveals a significant effect of the transgene (p<0.05) on coupled (state 3 and 4) and FCCP-induced uncoupled
respiratory rates of mitochondria from 24 month old P301L tau mice compared to age-matched WT controls by using the
specific complex I substrates malate/glutamate. Thus, aged, but not 12 month old, P301L tau mice exhibit a significant
impairment of complex I related respiration (*p<0.05 vs. corresponding WT control, Student’s t-test), while respiratory
rates after addition of the complex II substrate succinate are unchanged. Values represent means  S.E. from n=4
animals per group (measurement of WT control and P301L tau in parallel). All experiments were performed in duplicate
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month old P301L tau mice (Fig. 16A, B, lower panels each), leading to a markedly reduced
respiratory control ratio compared to age-matched WT mice (Fig. 17A). The respiratory control
ratio provides a measure for the efficiency of coupling of the mitochondrial respiratory chain,
indicating that the relative efficiency of metabolic coupling of the electron chain complexes is
impaired during ageing in P301L tau mice. In addition, after uncoupling with FCCP, the
respiratory rate in the absence of a proton gradient was significantly diminished in 24 month old
P301L tau mice (Fig. 16B, lower panel), indicating a reduced maximum capacity of the electron
transport chain. After complete inhibition of complex I with rotenone, succinate was added as a
substrate for complex II. No difference in respiratory rate could be observed between transgenic
and WT mice showing that complex II is not impaired by P301L tau.
In accordance with the respiratory control ratio, ATP levels of cerebral cells were unchanged in
12 month old P301L tau transgenic mice, but significantly reduced with ageing (Fig. 17B).
Together these results suggest that P301L tau mice exhibit an initial defect in mitochondrial
function with reduced complex I activity, which with age is translated into a mitochondrial
respiration deficiency with diminished ATP synthesis corresponding to reduced complex V
activity.
Figure 17.: Reduced respiratory control ratio and impaired ATP synthesis in P301L tau mice with aging. A,
Reduced respiratory control ratio in 24 month old P301L tau mitochondria (*p<0.05 vs. age-matched WT
control mice, Student’s t-test), indicating an impaired efficiency of electron transport in aging. Values
represent means  S.E. from n=4 animals per group. All experiments were done in duplicates. B, In
accordance, cerebral ATP levels are significantly reduced in 24 month old P301L tau mice (*p<0.05 vs. age-
matched WT control mice, Student’s t-test). Two-way ANOVA reveals a significant effect of the transgene
(p<0.05) on ATP levels. Values represent means  S.E. from n=6-7 animals per group.
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Mitochondrial dysfunction is not coupled to alterations in the number of mitochondria in
P301L tau mice. Evaluation of the amount of mitochondria in cerebral brain cells revealed no
difference between P301L tau and WT mice either in the cerebrum (Fig. 18A) or in the
cerebellum (data not shown). In addition, co-immunostaining of mitochondria and microtubules
and subsequent counting of the mitochondria in proximal and distal parts of neurites in the CA1
region of the hippocampus also showed no variation between P301L tau and WT mice (Fig.
18B). These data suggest that mitochondrial dysfunction is not associated with reduced
mitochondrial numbers or significant changes in transport of mitochondria along neurites.
Figure 18.: Unchanged number of mitochondria. A, Measuring the amount of mitochondria using the cell-
permanent mitochondrion-selective dye Mitotracker Green reveals no differences between P301L tau and
WT mice in cerebrum. Values represent means  S.E. from n=8 animals per group. B, immunostaining of
mitochondria and microtubules in CA1 hippocampal brain sections with anti-porin (Cy3, in red) and anti-
tubulin antibodies (Cy2, in green) again reveals no statistical difference in mitochondrial neuritic numbers
at proximity or distally to the cell body between 18 month old P301L tau and WT mice. Values represent
means  S.D. from n=4 animals per group where mitochondria were counted in four different neurites per
animal. Scale bar represents 50 µm.
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Aβ insult causes increased membrane potential reduction in P301L tau mitochondria.
Extracellular Aβ treatment of PC12 cells has been shown to lead to a significant decrease in
mitochondrial membrane potential (Keil et al., 2004). In order to investigate whether brain cells
from P301L tau mice are more susceptible to Aβ, we measured the mitochondrial membrane
potential of isolated cortical brain cells with and without Aβ treatment. Interestingly, the basal
mitochondrial membrane potential was still conserved in cerebral cells from P301L tau mice.
However secondary insult with Aβ1-42 resulted in a higher reduction in membrane potential in
P301L tau mitochondria than in WT (Fig. 19A). Importantly, this effect is brain region-specific
and therefore probably dependent on the presence of P301L tau since cells from cerebellum with
very low P301L tau expression levels were not vulnerable to this damage (Fig. 19B). This data
suggests a synergistic action of Aβ and tau pathology on mitochondrial function.
Figure 19.: Brain region-specific decrease of membrane potential after secondary insult with 50 nM Aβ.
Aged, aggregated preparations of Aβ1-42 were given to brain cells as secondary insult. An increased
reduction of ∆m was observed with the addition of Aβ to cerebral cells (A) (*p<0.05 vs. WT control mice,
Student’s t-test), but not with cerebellar cells (B) from 12 month old P301L tau mice. Two-way ANOVA
reveals a significant effect of the transgene (p<0.05) on changes of mitochondrial membrane potential in
cerebral cells. Values represent means  S.E. from n=6-7 animals.
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3.3.3 Oxidative stress
Increased tau pathology causes higher oxidative stress, modified lipid peroxidation levels
and up-regulation of antioxidant enzyme activities in P301L tau mice. In P301L tau mice,
these mitochondrial defects are associated with increased ROS formation, as both staining with
DHE for detection of superoxide anions as well as staining with H2DCF-DA for detection of
cytosolic peroxides were increased (Fig. 20A, B).
Figure 20.: Increased ROS production. A, Increases in superoxide anion radicals determined by DHE
oxidation. Fluorescence (arbitrary units) normalized for protein content in brain cells from hemizygous P301L
tau mice was measured after incubation of samples with DHE for 15 min. Two-way ANOVA: p < 0.01 effect
of transgene, age and interaction n.s. Bonferroni post test: * p < 0.05 WT versus hemizygous P301L tau
mice. B, Increases in cytosolic H2O2 determined by H2-DCF oxidation. Fluorescence in brain cells from
hemizygous P301L tau mice was measured after incubation of samples with H2-DCF-DA for 15 min. Two-
way ANOVA: p < 0.01 effect of transgene, age and interaction n.s. Bonferroni post test: * p < 0.05 WT
versus hemizygous P301L tau mice. C, Reduced lipid peroxidation in P301L tau brains under basal
conditions determined by MDA levels (nmol/mg protein). Two-way ANOVA: p < 0.01 effect of transgene, p <
0.05 age group, p < 0.05 interaction. Bonferroni post test: *** p < 0.001 WT versus homozygous P301L tau
mice (P301L/P301L). D, Increased lipid peroxidation under stimulated conditions in 24 month old
homozygous P301L tau mice. Formation of MDA (nmol/mg protein) in brain homogenates after 30 min
incubation with FeCl3 is increased in samples from P301L tau mice. Two-way ANOVA: p < 0.05 effect of
transgene, age and interaction n.s. Bonferroni post test: * p < 0.05 controls versus homozygous P301L tau
mice. All values represent means  S.E. from n = 6-9 animals per group (except for 12 month old
homozygous, n = 3).
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Increased ROS levels could be detected already in 12 month old P301L tau mice but were more
pronounced and statistically significant in 24 month old mice correlating with the age-specific
increase in tau pathology. As a measure of free radical damage to critical cellular components,
levels of malondialdehyde (MDA) as lipid peroxidation end product were determined. Despite
increased ROS levels, basal levels of MDA were decreased in 24 month old hemizygous P301L
tau mice and more pronounced in homozygous mice indicating that ROS levels are met by
adequate antioxidant defences in these mice (Fig. 20C). However, upon stimulation with ferric
iron, increased MDA levels were formed in P301L tau mice (Fig. 20D). This effect was already
observed in 12 month old mice, but was more pronounced and statistically significant in 24
month old homozygous mice. Furthermore, basal and stimulated MDA levels remained
unchanged in the cerebellum of 24 month old hemi- and homozygous P301L tau and WT mice
(data not shown). As P301L tau is expressed at very low levels in the cerebellum (Gotz et al.,
2001a), we can conclude that modifications in lipid peroxidation are specifically caused by the
presence of the P301L tau protein. Hence, the presence of mutant tau impairs antioxidant defence
under conditions of increased oxidative stress.
As a direct measure of antioxidant defence, activities of antioxidant enzymes were determined.
While no significant changes were observed in 12 month old mice, 24 month old homozygous
P301L tau mice displayed increased activities of Cu/Zn-superoxide dismutase (Cu/Zn-SOD) and
glutathione reductase (GR) (Fig. 21A, C), while the activity of glutathione peroxidase (GPx) was
not significantly increased (Fig. 21B). The increased enzyme activities may provide protection
against ROS damage under basal conditions, but are obviously not sufficient to eliminate lipid
peroxidation damage caused by the in vitro stimulation of brain homogenates with ferric iron. It
is important to note that modified lipid peroxidation levels and increased antioxidant enzyme
activities are dependent on the levels of P301L tau pathology as these changes were only detected
as significant in old homozygous P301L tau mice.
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3.4 Proteomic analysis of P301L tau overexpressing SH-SY5Y cells treated with
ß-amyloid
To assess the effects of Aβ on the proteome of SH-SY5Y cells overexpressing tau protein, we
homogenised five samples treated with Aβ and five samples treated with reverse Aβ, and
sequentially extracted them into two fractions. In order to directly identify protein spots from the
Figure 21.: Altered levels in detoxifying enzymes. A, Increased Cu/Zn-SOD activity in 24 month old
homozygous P301L tau mice. Two-way ANOVA: effect of transgene n.s., p < 0.05 age group, p < 0.05
interaction. Bonferroni post test: * p < 0.05 controls versus homozygous P301L tau mice. B, GPx activity.
Two-way ANOVA: p < 0.05 effect of transgene, age group and interaction n.s. C, Increased GR activity in
24 month old homozygous P301L tau mice. Two-way ANOVA: p < 0.05 effect of transgene, age group and
interaction n.s. Bonferroni post test: * p < 0.05 controls versus homozygous P301L tau mice. Values
represent means  S.E. from n = 6-9 animals per group (except for 12 month old homozygous, n = 3).
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gels used for the Proteomweaver analysis, Aβ and reverse Aβ treated fractions were isoelectrical
focused on 24 cm IPG pH 3-10 strips, which allowed us to load 100 µg S1 and 67 µl S2.
We have proved that Silver staining can be compatible with a 2-DE proteomic approach and
differences found between transgenics and WT mice can be confirmed by functional assays.
However Silver staining presents some major drawbacks mainly concerning the linear range of
staining and reproducibility. In comparison, Sypro Ruby, a ruthenium complex-based stain, offers
significant advantages over Silver staining by combining staining reproducibility, a linear
dynamic range of quantitation over three orders of magnitude and a detection limit of
approximately 1-2 ng protein/spot. This staining is also compatible with MS. Therefore we used
Sypro Ruby to detect protein spots in the fractions from Aβ treated SH-SY5Y cells.
Figure 22.: Proteomweaver analysis of supernatant S1 and S2 from SH-SY5Y cells treated with Aβ.
A, Spots up-regulated with Aβ reverse treatment in S1 fraction; B, Spots up-regulated with Aβ
treatment in S1 fraction; C, Spots up-regulated with Aβ reverse treatment in S2 fraction; D, Spots up-
regulated with Aβ treatment in S2 fraction.
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The software Proteomweaver was used to normalise all gels and to compare each 2-D spot
pattern of every gel from Aβ treated cells of one fraction with each 2-D spot pattern of every gel
from reverse Aβ treated cells of the same fraction. Only spots present in all 12 gels and
differentially regulated by at least 1.5 fold were considered for statistical analysis with Student’s
t-test (p < 0.05) (Fig. 22). We found in the supernatant S1 fraction, 9 spots up-regulated with Aβ,
of which two are only found in the Aβ treated samples; and 8 spots up-regulated with reverse Aβ.
In the supernatant S2 fraction, we found 34 spots up-regulated with Aβ and 28 spots up-regulated
with reverse Aβ. Regulated S1 and S2 spots await identification by MALDI-TOF/TOF MS.
3.5 Proteomic analysis of amygdalae from P301L tau mice injected with ß-
amyloid
P301L tau transgenic mice were intracranially injected with either Aβ or reverse Aβ. After three
weeks, the mice were sacrificed, the amygdalae were dissected and the hippocampus was fixed in
PFA. For each mouse, we checked the site of injection in the hippocampus by GFAP
immunostaining with detects the reactive astrocytes around the injection tract. For all mice, the
site of injection could be located to the CA1 region of the hippocampus although some injections
were slightly deeper.
As we have discussed in 3.1.1., prefractionation of samples before proteomic analysis is essential
to distinguish medium to low abundant proteins. Therefore we tried to adapt the sequential
extraction following protein solubility that was used for whole brains (see 3.1.1 and 3.2), to our
dissected amygdala samples. However we could not optimise the protocol to obtain distinct
fractions as a high level of overlap between fractions was observed (Fig. 23). It is important to
note that we used throughout the trials and for the final comparison, a small pH range of 5-8 for
IEF separation instead of pH 3-10. This should allow us to zoom in on lower abundant proteins
without loosing too many significant hits as indeed most proteins are concentrated in this pH
range on 2-D gels.
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Figure 24.: Amygdala extraction trial into S1 and S2 following the protocol used
for Aβ treated SH-SY5Y cells. Both S1 and S2 fractions were isoelectrically
focused on 11 cm IPG strips pH 5-8. A, S1 fraction. B, S2 fraction. Both fractions
show a high level of overlap in protein spots.
Figure 23.: Amygdala extraction trial into E1, E2 and E3 following the protocol used for P301L tau whole brain
samples. All fractions were isoelectrically focused on 11 cm IPG strips pH 5-8. A, E1 fraction. B, E2 fraction. C, E3
fraction. All fractions show a high level of overlap in protein spots.
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In a second step, we separated the amygdalae into two fractions, S1 and S2 following the
protocol that we established for Aβ treated SH-SY5Y cells. Again the 2-D patterns of S1 and S2
showed a high degree of spot overlapping (Fig. 24). Therefore we decided to extract amygdala
samples directly in IEF rehydration buffer without prefractionation. To improve protein
extraction and recovery, we tried three different homogenisation methods, 3 min sonication,
homogenisation using a syringe or homogenisation in a glass-teflon potter. Sonication gave the
best results.
After centrifugation of sonicated samples, the supernatant was collected and loaded on 24 cm
IPG pH 5-8 strips. Amygdala samples from five Aβ and five reverse Aβ injected mice were
isoelectrically focused simultaneously, separated on 12% SDS-PAGE gels and stained with
Sypro Ruby.
The 2-D patterns showed a high degree of similarity and were quantified with Proteomweaver.
Only spots present in all 10 gels and differentially regulated by at least 1.5 fold were considered
for statistical analysis with Student’s t-test (p < 0.05). We found 16 spots up-regulated with Aβ
and 10 spots up-regulated with reverse Aβ (Fig. 25). Regulated spots were directly picked out of
the gels used for the comparative study, digested and are in the process of being analysed by
MALDI-TOF/TOF MS.
Figure 25.: Proteomweaver analysis of amygdala from P301L tau transgenic mice injected with Aβ. A,
Spots up-regulated with Aβ reverse injection; B, Spots up-regulated with Aβ injection.
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3.6 Study of tau insolubility after proteasome inhibition in P301L tau
overexpressing SH-SY5Y cells treated with ß-amyloid
To evaluate potential consequences of proteasome inhibition on Aβ mediated tau insolubility, we
treated differentiated P301L tau expressing SH-SY5Y cells with various proteasome inhibitors.
We choose differentiated cells to minimise the effect of proteasome inhibitors on cell cycle and
apoptosis. First we tested different concentrations of proteasome inhibitors on differentiated SH-
SY5Y cells to determine which concentration does not induce significant cell death over 5 days.
We treated differentiated cells either with Aβ or PBS for 5 days together with or without different
proteasome inhibitors. The whole experiment with epoxomicin and lactacystin was carried out
three times.
Tau insolubility was evaluated by Western blotting of formic acid fractions obtained after a
sequential extraction of the collected cells. Fig. 26 shows representative blots. Although we
confirmed again that Aβ induces tau insolubility, results were too variable to show a significant
effect of proteasome inhibitors on tau insolubility together with Aβ. Indeed in Figure 26, Western
blotting of formic acid fractions from cells treated with lactacysin and Aβ, shows both an
Figure 26.: Formic acid fractions from differentiated P301L tau expressing
SH-SY5Y cells treated with Aβ and proteasome inhibitors. Blot were probed
with the human specific tau antibody HT7. Full-length tau is indicated by an
arrow and an asterisks marks the position of a 25 kDa truncated species
possibly also tau.
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increase and a decrease in levels of insoluble tau. This variability is probably due to a certain
amount of variability in the sequential extraction of tau which has been observed by several
members of the laboratory.
3.7 Study of tau phosphorylation in P301L tau mouse brains
Soluble tau is generally extracted by perchloric acid, based on tau’s acid stability. However, this
method is not compatible with MS analysis of tau phosphorylation as it oxidises tau amino acids.
Therefore we adapted a milder extraction method published by Köpke et al. (Kopke et al., 1993)
which separates the AD hyperphosphorylated tau (AD-P tau) from the cytosolic non-
phosphorylated tau and insoluble NFT tau.
First we evaluated the presence and level of tau in the urea soluble pellet obtained after 200,000 x
g centrifugation (Fig. 27). Western blotting showed us that indeed tau is present and one spot
picked from the 2-D gel was identified as tau protein by MS. However the 2-D pattern reveals
that a significant amount of other proteins are still present in this AD-P tau fraction. To remove
these, we performed a final 334,000 x g ultracentrifugation step with the urea solublised fraction.
We also isoelectrically focused the sample on IPG strips with a smaller pH range from 5 to 8,
where tau proteins should be present.
Figure 27.: Extraction for AD-P tau. P301L tau transgenic brain pellet from the 200,000 x g
ultracentrifugation step was resuspended in 8 M urea. 300 µg was loaded on a 17cm IPG strip pH 3-
10. Left.: 2-D gel of sample. Right.: Western blotting of 2-D gel probed with tau specific antibody, HT7.
Tau was identified in a spot picked from this 2-D gel.
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The 2-D pattern shows that this last centrifugation step is still not sufficient to remove most
contaminants (Fig. 28). We also did not observe a significant amount of protein spots in the pI
and molecular weight region for tau, which differed between P301L tau transgenic and WT
samples. We therefore conclude that this extraction method is not sufficient in its present form, to
provide an AD-P tau separation pure enough to dissociate most of the tau species present for MS
analysis of phosphorylation.
3.8 PipOFF system
Our goal in this study was to assess whether the PipOFF transactivation system developed by
Prof. Fussenegger for mammalian cell culture, would also work in the mouse model. We
generated several double transgenic mice with the PIT gene under the control of either the EF1α
or the CMV/β-actin promoter and the PPIR8 promoter controlling expression of either the
reporter gene YFP, GFP or LacZ.
First we tested the PipOFF transactivation in cell culture with the EF1α-PIT and PPIR8-YFP
constructs. After transfecting cells with both plasmids using the Gene Gun, we observed about
10% of cells expressing YFP (Fig. 29). YFP expression was turned off only after treatment with
20 times more PI as originally published (Fussenegger et al. (2000) Nature Biotechnology 18,
Figure 28.: Extraction of AD-P tau. 200,000 x g pellet was resuspended
and centrifuged at 334,000 x g. The supernatant (80 µl) was loaded on a 17
cm IPG strips pH 5-8. 2-D gel shows that the tau extract still contains a
wide variety of other proteins.
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1203-1208). This could be due to differences in the dissolution protocol of the PI. All together
this proves that the PipOFF system functions in cell culture with these constructs.
Figure 29.: 3T3 cells transfected with EF1α-PIT and PPIR8-YFP constructs using a GeneGun.
Left, non-treated cells expressing both constructs. Right, cells treated with 20 µg/ml PI from
Pyostacin tablets (Aventis). YFP is expressed in the absence of PI and knocked down by the
treatment with PI demonstrating that the PipOFF transactivation system works with these
constructs and can be turned off.
Figure 30.: Generation of double transgenic EF1α-PIT and PPIR8-YFP mice.
In the absence of pristinamycin PI, PIT protein should bind to the PPIR8
promoter and induce transcription of YFP. In the presence of PI, PIT should no
longer promote YFP expression.
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To generate transgenic mice with the PipOFF system, we co-injected both EF1α-PIT and PPIR8-
YFP constructs to produce double transgenic mice (Fig. 30). Transmission from the founders to
the F1 generation was unusually low with only one of the six positive double transgenic founders
that gave double positive pups. We also obtained two single PIT transgenic founders from co-
injections. We tried feeding the female double transgenic founders in mating with dry food
pellets containing PI to inhibit YFP expression during the embryonic period. However this did
not result in transmission of the transgenes to the offspring, suggesting that a least YFP
expression is not lethal during development.
In the positive founders, we could not observe any YFP fluorescence in ear cuttings under the
microscope. Therefore we carried out immunohistochemistry on tail cuttings. However, we also
could not detect any YFP expression in the tails of any of the double transgenic EF1α-PIT and
PPIR8-YFP founders. In order to detect low quantities of YFP, we did a Western blot with
different organs from a double transgenic mouse (Fig. 31). However we could not detect a band
at 28 kDa or any higher bands specifically expressed in the PCR positive animal. We also probed
for PIT protein with an antibody against the transactivation part VP16. Fig. 31 shows a band in
Figure 31.: Western blot of double transgenic EF1α-PIT and PPIR8-YFP offspring (co-
injected of both constructs). Left: probed with an anti-VP16 antibody. Arrow indicates the
potential PIT band. Right: probed with an anti-GFP antibody. L: lung, Li: liver, H: heart, B:
brain.
84
the lung and heart of the PCR positive animal but this band is slightly higher than the theoretical
47 kDa molecular weight for PIT. Subsequently, we produced single transgenics PPIR8-YFP and
crossed these with single PIT transgenics which had only integrated the PIT construct from the
EF1α-PIT and PPIR8-YFP co-injection. Here a normal transmission rate of the transgenes was
observed. However, we could not detect the expression of PIT or YFP by Western blotting (data
not shown).
Figure 32.: Western blots of double transgenic EF1α-PIT and PPIR8-GFP mice with the VP16
antibody to detect PIT protein. PIT protein (47 kDa) is detect in the positive control from cells
transfected with EF1α-PIT as the second strongest band. A similar MW band can be detected in lung
and kidney tissue but is present in both PCR positive and negative animals.
H: heart, L: lung, K: kidney, M: muscle, +: positive cell lysate control.
Figure 33.: Western blots of double transgenic EF1α-PIT and PPIR8-GFP mice with the GFP antibody.
YFP protein (28 kDa) is detect in the positive control from cells transfected with EF1α-PIT and PPIR8-YFP.
No similar MW band can be detected the PCR positive animal tissues (both GFP and YFP are of similar
MW). H: heart, L: lung, K: kidney, M: muscle, +: positive cell lysate control.
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Background fluorescence in vivo has been shown to be decreased using the longer wavelength
needed to detect YFP compared to that used for GFP. However, GFP expression is easier to
detect in the mice as a simple UV light is needed. Therefore, we also produced in parallel single
PPIR8-GFP transgenic mice. These mice were crossed with the EF1α -PIT single transgenic line.
But again we did not detect expression of GFP or PIT on Western blots of various organs from
the double transgenic mice. The positive control in Fig. 32 shows a band at the right size for PIT
(47 kDa). A similar band is present in lung and kidney from both PIT positive animals but also in
the negative control animal. Furthermore we can distinguish various higher molecular weight and
stronger bands, suggesting that the VP16 antibody is cross reacting with other proteins present.
Western blotting with the GFP antibody (Fig. 33) presents a strong band at about 40 kDa in the
positive cell lysate control, whereas the calculated molecular weight of GFP and YFP is around
28 kDa. We have demonstrated that the cells double transfected with EF1α-PIT and PPIR8-YFP
express YFP. Therefore this slightly higher band detected in the positive control is most probably
YFP. Both PCR positive animals do not show any GFP bands at this height or any other bands
that are different from the PCR negative animal.
Following the failure to produce double transgenic mice expressing YFP or GFP with the PipOFF
system, we decided to change both the promoter controlling PIT expression and the reporter
gene. We chose the more ubiquitous and strong promoter, CMV/β-actin promoter to control PIT
expression and we changed the reporter gene to LacZ. The CMV/β-actin-PIT and PPIR8-LacZ
constructs were co-injected to produce double transgenic mice. 106 double CMV/β-actin-PIT and
PPIR8-LacZ co-injected founders were generated. LacZ ear staining was first carried out,
showing positive staining of certain founders. However repetition of the staining revealed a high
variability. Furthermore, LacZ staining of cryostat sections from different organs of mice
identified as positive by ear staining was negative. PCR for PIT and LacZ demonstrated that only
two founders were LacZ positive and only one was transgenic for both LacZ and PIT. However
LacZ staining of ear tissue from the double positive was negative. Furthermore the mouse died
before giving offspring.
We also tried to generate single CMV/β-actin-PIT transgenic mice. Mice implanted with embryos
gave very low numbers of offspring. Despite a generally impressive track record with other DNA
constructs, we could only obtain 16 offspring of which none were PIT positive. As the generation
of double EF1α-PIT and PPIR8-YFP transgenic mice unexpectedly also gave very few double
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positive mice, we can conclude that the PIT construct in itself is probably not integrating into the
genome and disturbs the integration of the other construct.
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4 DISCUSSION
4.1 Analysis of P301L tau mouse brains
The P301L mutation of tau is one in a set of mutations implicated in FTDP-17 (Spillantini
et al., 2000). This mutation reduces the ability of tau to interact with microtubules and promotes
the assembly of tau into filaments in vitro. In our P301L tau transgenic mice, tau filaments start
to accumulate at about six months of age preceded by distinct hyperphosphorylation of tau (Gotz
et al., 2001a; Gotz et al., 2001b). Furthermore, the tau pathology causes specific behavioural
deficits in the mice related to the amygdala, an area with prominent NFT formation (Pennanen et
al., 2004).
Proteomics is becoming more and more widely used to study brain changes under physiological
and pathological conditions such as in AD (Butterfield et al., 2003; Schonberger et al., 2001).
Considering the complexity of brain tissue, we adapted a sequential extraction method to separate
the brain proteins according to solubility before proteomic analysis (Molloy et al., 1998). This
approach followed by functional analysis of the P301L tau mice suggests that tau accumulation,
in the absence of massive NFT formation, induces a mitochondrial dysfunction. The down-
regulation of nuclear encoded subunits of electron transport chain complexes I and V was
accompanied by a reduced depolarisation of mitochondria from 12 month old P301L tau mice
after treatment with the complex I inhibitor rotenone and the complex V inhibitor oligomycin.
We could also demonstrate a direct decrease in complex I activity. At this age, the other
mitochondrial respiratory chain complexes seemed to be able to compensate since the respiratory
control ratio and mitochondrial membrane potential remained unchanged. However following the
increase of tau pathology with ageing, this compensation is no longer sufficient and mitochondria
from 24 month old P301L tau mice exhibited an impaired efficiency of coupling between the
mitochondrial respiratory chain complexes, diminished capacity in electron transport and a
significant reduction in ATP levels. In particular, the reduction in state 3 respiration reflects a
reduced capacity of mitochondria to metabolise oxygen and the complex I substrate in the
presence of a limited quantity of ADP. Thus, there is also a clear complex I deficiency in the
mitochondrial respiration at 24 months of age.
Our results correlate with previous studies on AD, suggesting partial mitochondrial uncoupling
(Sims et al., 1987), modifications of mitochondrial encoded complex I subunit mRNA (Aksenov
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et al., 1999; Li et al., 2003) and reduction in protein levels of the 24 and 75 kDa subunits of
complex I (Kim et al., 2001) as well as diminished ATP synthase (complex V) levels (Schagger
and Ohm, 1995). As demonstrated in primates, complex I activity has been shown to be reduced
with ageing which could potentially intensify complex I activity defects in the P301L tau mice
(Bowling et al., 1993). Furthermore, we could show a clear-cut reduction in levels of complex V
in human P301L FTDP-17 brains compared to control human brains. This important finding
confirming the decrease in complex V identified twice in our proteomics analysis of the P301L
tau mouse argues in favour of a potential mitochondrial dysfunction in human FTDP-17 patients.
This result also emphasises the relevance of our P301L tau mouse as a model of the human tau
pathology.
Our proteomic analysis revealed also modifications in levels of TPI, cytoplasmic malate
dehydrogenase and inorganic pyrophosphatase implying a broader metabolic disorder possibly
encompassing the glycolysis cycle. The glycolytic enzyme TPI can bind to microtubules (Orosz
et al., 2000), and higher levels of nitrated TPI have been found in AD brains (Castegna et al.,
2003). Consistent with an overall metabolic failure, several reports using positron emission
tomography (PET) revealed reduced glucose metabolism in AD and frontotemporal dementia
(FTD) brains (Diehl et al., 2004; Grimmer et al., 2004; Jagust et al., 1991; Mielke et al., 1996;
Santens et al., 2001). Notably, high levels of phosphorylated tau have been linked to glucose
hypometabolism in mild cognitively impaired patients (Fellgiebel et al., 2004).
Together, this evidence supports a role of tau pathology in mitochondrial and metabolic
dysfunction. However, it remains unclear how tau accumulation mediates these changes.
Overexpression of WT tau in cell culture caused impairment of plus-end-directed transport
resulting in a reduction of mitochondria levels in the neurites (Ebneth et al., 1998). Although we
can not exclude this occurring in the P301L tau mice, mitochondrial neuritic numbers counted at
proximity or distally to the cell body, did not vary significantly compared to WT numbers.
Furthermore, the total amount of mitochondria remained unchanged as measured in brain cells of
transgenic compared to control mice. This suggests that either P301L tau induces a different
pathological mechanism than overexpressed WT tau or that tau action on mitochondria transport
in cell culture cannot be extrapolated over to the mouse model. Consistent with these findings,
similar numbers of mitochondria were reported between NFT and non-NFT bearing cells in AD
(Sumpter et al., 1986). Alternatively, tau accumulation could have direct repercussions on the
mitochondria as the accumulation of increasingly insoluble ATP synthase α-chain together with
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NFT has been shown in AD brains whereas detergent soluble levels were reduced (Sergeant et
al., 2003). Overall it is important to note that the mitochondrial pathology in the P301L tau mice
observed in this study is unlikely to be a direct consequence of tau hyperphosphorylation. Indeed
the transgene levels of expression in these mice are relatively low (Gotz et al., 2001a) and
depletion of ATP solely due to tau hyperphosphorylation would be improbable.
We furthermore demonstrate that accumulation of P301L tau causes significant
modifications in the oxidative state of the brain. ROS measurements revealed increased levels of
cytosolic H2O2 and superoxide anion radicals in two year old P301L tau mice. These increased
ROS levels may be a direct consequence of reduced complex I activity in P301L tau mice, as
inhibition of complex I can lead to increased superoxide formation (Turrens and Boveris, 1980).
The increased activity of Cu/Zn-SOD measured in P301L tau mice should ameliorate the
accumulation of superoxide but also gives rise to H2O2, which is then insufficiently processed by
GPx leading to accumulation of peroxides. Accordingly, the relative increase in H2O2 in P301L
tau mice was much more pronounced than the increase in superoxide radicals. Somewhat
unexpectedly, along with increased tau pathology we observed decreased levels of the lipid
peroxidation product MDA as a marker for ROS damage to cellular membranes, in old
homozygous P301L tau mice despite increased levels of ROS. One potential explanation for this
discrepancy could be that the cells affected by lipid peroxidation are removed by apoptosis,
although we could not detect major differences in levels of apoptotic cells detected by TUNEL
staining (data not shown). As several steps lead from ROS accumulation to lipid peroxidation
damage, another possibility would be that the up-regulation of antioxidant activities of Cu/Zn-
SOD and glutathione reductase (GR) in P301L tau mice may intercept ROS before they can
critically damage membranes. As previously reported, rising Cu/Zn-SOD and GR activities in
aged mouse brains can protect against lipid peroxidation (Schuessel et al., 2005). Furthermore,
SOD can prevent lipid peroxidation both in vitro and in vivo (Bonnes-Taourel et al., 1993;
Gutteridge, 1984; Gutteridge et al., 1983; Liu et al., 2003; Tien et al., 1981). Similarly, increased
GR activity in P301L tau mice may protect against accumulation of MDA by increasing levels of
the antioxidant reduced glutathione. In several experimental models, increased levels of reduced
glutathione were associated with lower levels of lipid peroxidation products and vice versa
(Comporti, 1987; Younes and Siegers, 1980). Upon in vitro stimulation, however, higher levels
of MDA were formed in homozygous P301L tau brain homogenates. Obviously, the increased
activities of Cu/Zn-SOD and GR were not sufficiently protective under these conditions. This
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may be explained by a relative lack in GPx activity, as the accumulation of H2O2 observed in
brains from P301L tau mice combined with the exogenously added ferric iron can lead to
increased formation of hydroxyl radicals via Haber-Weiss and Fenton reactions. Reports on lipid
peroxidation in brains from patients with tauopathies are inconsistent. Although increased levels
of the lipid peroxidation product HNE were found in patients with progressive supranuclear palsy
(Odetti et al., 2000) and tau was colocalised with MDA immunoreactivity in AD patients (Dei et
al., 2002), another study reported increased lipid peroxidation products specifically in AD
patients, but not in patients with FTD (Yao et al., 2003). Therefore, tau pathology may not be
associated inevitably with lipid peroxidation processes in human brain tissue, consistent with our
observations in P301L tau mice. Most studies have reported an up-regulation of antioxidant
enzyme activities in AD (Lovell et al., 1995). These changes were most pronounced in brain
regions that are severely affected by AD pathology (Karelson et al., 2001; Lovell et al., 1995;
Schuessel et al., 2004).
Our proteomic analysis also suggests changes in cellular antioxidant mechanisms as
shown by variations in spots representing the antioxidant enzymes perioredoxin 3, peroxiredoxin
6, GST P2 and Mu1, and PHGPx. Peroxiredoxin reduces peroxides including H2O2, GST
catalyses the conjugation of reduced glutathione to a wide number of molecules and PHGPx
directly reduces peroxidized phospholipids in membranes (Ursini et al., 1985). Although all these
protein spots were down-regulated in the P301L tau mouse, this does not necessarily reflect
enzyme activities. Besides, under oxidative conditions, these antioxidant enzymes are prone to
oxidative modifications represented by a set of distinct spots on 2-D gels as suggested for
peroxiredoxin which undergoes overoxidation (Chevallet et al., 2003; Wagner et al., 2002). The
thioredoxin/thioredoxin reductase system mediates the regeneration of oxidised peroxiredoxins
and to some extent glutathione peroxidases (Nordberg and Arner, 2001). However AD brains
show decreased thioredoxin levels and increased thioredoxin reductase levels (Lovell et al.,
2000). Therefore the dysfunction of this system could cause an accumulation of oxidative
modification in peroxiredoxins. Interestingly, AD brains also show decreased GST activity
(Lovell et al., 1998) and GST omega-1 mRNA levels in AD (Li et al., 2003), and single
nucleotide polymorphisms (SNPs) in GST omega-1 are associated with age-at-onset in AD (Li et
al., 2003).
Hence both our functional and proteomic data indicate a complex regulation and potential
malfunction of the cellular antioxidant defence mechanisms in response to increased ROS levels
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in this mouse model. As mitochondrial dysfunction appears prior to oxidative stress, this suggests
that it is probably the initiating factor. However we can speculate that both mitochondrial
dysfunction and oxidative stress act in synergy creating a vicious cycle. Indeed increases in ROS
and antioxidant enzyme dysfunction could affect the integrity of the mitochondria and in
particular, the electron transport chain (Keil et al., 2004). Furthermore glutathionylation of
complex I in oxidative conditions leads to increased superoxide production (Taylor et al., 2003).
Another possible consequence of higher oxidative stress levels could be an acceleration of tau
pathology (Hartzler et al., 2002; Perez et al., 2000). Moreover, tau can be readily oxidised by
H2O2 to form disulfide linked species which manifest reduced propensity to promote microtubule
assembly (Landino et al., 2004b). Oxidised tau then becomes a substrate of the thioredoxin
reductase and glutathione/glutaredoxin reductase systems (Landino et al., 2004a; Landino et al.,
2004b). Thereby we can speculate that the accumulation of oxidised P301L tau might overload
these antioxidant regenerating systems causing further oxidative stress.
Results from our proteomic study further suggest a potential synaptic dysfunction as we
found an up-regulation of a series of synaptic related proteins. The identified DRP-2 is known to
promote axonal growth by interaction with the tubulin heterodimer and has also been shown to
induce neurite formation (Fukata et al., 2002; Inagaki et al., 2001). Synapsin I is thought to
regulate the reserve pool of synaptic vesicles (Gitler et al., 2004). The septin member, CDCrel-1
is found mainly in inhibitory presynaptic terminals and inhibits exocytosis (Beites et al., 1999;
Kinoshita et al., 2000). Interestingly, both DRP-2 and septin associate with NFT in AD
(Kinoshita et al., 1998; Yoshida et al., 1998). Therefore in response to tau pathology, the
transgenic mouse neurones may be attempting a compensatory mechanism by increasing synaptic
vesicle control proteins and potentially aberrant synaptic sprouting. Indeed, although advanced
stages of AD are associated with synaptic loss, an initial increase in synaptic protein levels in AD
brains was observed which was correlated with the appearance of the tau pathology but not with
Aβ plaques (Mukaetova-Ladinska et al., 2000). On the contrary, a decrease of synaptic proteins
occurred only after the appearance of the full spectrum of tau and Aβ pathology. Although it is
uncertain exactly how tau mechanistically affects synapses, we can postulate that either the
mutant tau acts by modifying microtubule stability and axonal transport or by inhibiting energy
production through complex I in the synapses. Indeed a reduction in activity of complex I by only
25% has been shown to impair energy metabolism in synaptic mitochondria (Davey et al., 1998),
whereas at least 72% is needed in non-synaptic mitochondria (Davey and Clark, 1996). In this
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study, our mitochondrial isolation does not include synaptic mitochondria. It would be interesting
to measure complex I activity and mitochondrial respiration in a pure synaptosomal
mitochondrial preparation.
We were not able to show by either Western blotting or immunostaining a significant up-
regulation of DRP, CDCrel-1, synapsin or synaptophysin due to high levels of variability
between individual mice. Observation of the number of synapses using Golgi staining might
allow a quantification between P301L tau and WT mice. It would also be worthwhile to carry out
electrophysiology as this should show whether the P301L tau mice have dysfunctional synapses
due to aberrant synapse sprouting.
In addition to the three major categories, mitochondrial proteins, antioxidant enzymes and
synaptic proteins, we could identify by proteomics, several other proteins modified by the
presence of the P301L tau and potentially linked to AD pathology. The up-regulated MSTI1
mediates assembly of HSP70/HSP90 (Scheufler et al., 2000). A proteomic study has shown
modifications in various chaperone levels in AD brain (Yoo et al., 2001b). In addition, levels of
HSP αB-crystallin, HSP27 and HSP60 were found to be increased in tauopathies with glial
pathology (Dabir et al., 2004). Decreased in the P301L tau mouse brain proteome pattern is
GRB2, an adapter protein which is involved in the activation of the MAPK signalling pathway,
through interaction with son-of-sevenless (SOS). Interestingly, AD brains show higher amounts
of GRB2 than control (McShea et al., 1999; Russo et al., 2002) and a differential cellular
distribution of GRB2 was observed as being more confined to the cell body (McShea et al.,
1999). Levels of the microtubule destabilising protein stathmin have been found to be negatively
correlated with NFT numbers in AD neocortex (Jin et al., 1996) and were also down-regulated in
the P301L tau mice. Another interesting down-regulated candidate is the probable D-tyrosyl-
tRNA deacylase, which removes D-tyrosine and other D-amino acids from charged tRNAs (Yang
et al., 2003). This enzyme carries out an essential role in protein synthesis proof-reading by
protecting against the incorporation of D-amino acids into proteins and could be relevant to AD.
Indeed studies have shown increased D-aspartate in AD grey matter compared to control, higher
levels of D-aspartate in PHF-tau, and the presence of D-aspartate in Aβ isolated from AD brains
(Fisher et al., 1992; Kenessey et al., 1995; Roher et al., 1993). Moreover, we could identify two
other proteins down-regulated and potentially related to synapse function. The β-alanine
oxoglutarate aminotransferase homologue (GABA transaminase) is involved in the metabolism
of GABA (Jeon et al., 2000) and γ-SNAP (γ-soluble N-ethylmaleimide-sensitive factor (NSF)
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attachment protein) is implicated in vesicle trafficking through its interaction with NSF and Gaf-
1/Rip11 (Tani et al., 2003). However, a proteomic study with AD brain samples did not reveal a
significant modification in γ-SNAP levels (Yoo et al., 2001a).
Finally, our data from the proteomic and functional study of the P301L tau transgenic
mouse should help to better distinguish between the respective pathological actions of Aβ and tau
protein. Numerous studies indicate that Aβ also causes oxidative stress and mitochondrial
malfunction (Anandatheerthavarada et al., 2003; Blanchard et al., 2003; Keil et al., 2004; Keller
et al., 1997). In particular, Aβ has been shown to generate free radicals in vitro (Hensley et al.,
1994) and reduces mitochondrial respiration through inhibition of cytochrome c oxidase activity
(Casley et al., 2002; Keil et al., 2004). We show here that Aβ causes increased reduction of
mitochondrial membrane potential in P301L tau mouse cerebrum compared to wild-type.
Importantly, this is not observed in the cerebellum of P301L tau mice, a brain area with very low
levels of transgenic tau. This could partially explain that injection of fibrillar Aβ peptide into the
hippocampus of P301L tau mice accelerated NFT formation in the amygdala, in line with the
amyloid cascade hypothesis (Gotz et al., 2001b). Therefore both tau and Aβ accumulation
probably act in synergy on oxidative stress and mitochondrial dysfunction.
In conclusion, our study helps understand the pathological consequences of tau alone,
suggesting that not only Aβ but also tau accumulation acts on the metabolism of the brain and the
oxidative conditions in AD. This implies that it will be important to address the treatment and/or
removal of both Aβ and tau pathology to efficiently treat AD patients.
4.2 Proteomic analysis of the action of ß-amyloid on P301L tau overexpressing
SH-SY5Y cells and P301L tau transgenic mouse amygdalae
Aβ causes the specific phosphorylation of certain epitopes on the tau protein, in both
amygdalae of P301L tau transgenic mice injected intracranially with Aβ and cells overexpressing
P301L tau treated with Aβ (Ferrari et al., 2003; Gotz et al., 2001b). In the cellular system, Ferrari
et al. (Ferrari et al., 2003) could also demonstrate that Aβ induces tau insolubility, which was
estimated by Western blotting after sequential extraction of the samples. Finally in both systems,
our group could show that Aβ induces tau filament formation.
In another cellular system, DeTure et al. showed increases in tau insolubility and the
formation of tau filaments in H4 neuroglioma cell overexpressing the mutant tau V337M
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compared to expressing the R406W mutation or wild-type tau (DeTure et al., 2002). In this
system and in the tau mutant transgenic mice, tau filament formation (15-25 nm in diameter) is
induced in the absence of Aβ and is probably due to a combination of high levels of tau and the
potentiation of fibrillogenesis caused by the presence of the mutation. However no other group
has been able to demonstrate until now, an induction of tau insolubility caused by Aβ in cell
culture. This may be due to difficulties in obtaining the right amount of tau expression in cell
culture as especially high levels of tau protein causes on its own, an increase in tau insolubility as
has been observed by other members of our group. On the other hand, Aβ induced tau filament
formation by intracranial Aβ injection in the mouse model has been reproduced by Walzer et al.
(Walzer et al., 2003) also using a transgenic mouse expressing P301L tau. This study showed that
the total phosphorylated sarcosyl insoluble tau protein levels were increased by Aβ injection. In
both the cell culture and mouse model, we did not observe significant high levels of cell death
induced by Aβ. Therefore the analysis of both systems should bring insight into the consequences
of exposure to Aβ without strong unspecific effects due to cell death.
Aβ has been shown to cause a wide array of specific effects in the cell (see 1.2.2.).
Whereas we should observe direct effects of Aβ in the cell culture system, it still remains unclear
whether the injection of Aβ in the P301L tau mouse hippocampi, mediates a direct or indirect
effect to the amygdala as no immunoreactivity of Aβ was detected in the amygdala. It is however
possible that small non-detectable quantities of Aβ are either transported by diffusion or by the
hippocampal projections into the amygdala.
In the cellular system, we show that Aβ causes relatively few significant differences in the
cytoplasmic proteins although we could detect two spots only in the Aβ treated fraction. This is
however two times more differentially regulated spots than in the proteomic study of the
cytoplasmic fraction from untreated P301L tau mice, although we used five pairs of replicates
instead of six pairs as in the mouse model. On the contrary, the pellet showed a large number of
differentially regulated spots. This could be due to the presence of Aβ which is observed as a
vertical streak (see Fig. 22, D). Indeed although we centrifuged the sample, it is possible that
some Aβ solubilises in the urea, CHAPS solution. Relatively large quantities of Aβ compared to
other proteins, could be modifying the isoelectrical focusing in the neighbouring pH range.
Indeed most significant up and down-regulated proteins are located in the pH region around the
Aβ vertical streak. The identity of the proteins should help us decide whether these are unspecific
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differences or not. If so, it would be probably best to only consider protein spots away from this
pH range.
Comparison of amygdala samples from Aβ or reverse Aβ injected P301L tau mice, show
relatively few statistical differentially regulated spots compared to the cellular system, although
we used a small pH range (pH 5-8) to focus on lower abundant protein changes. This could be
due to the fact that differences are hidden by the relatively large amount of proteins concentrated
in this sample as we did not perform a fractionation of the sample. This further underlines the
importance of sample fractionation before proteomic analysis. However in this study, we were
unable to optimise a fractionation protocol following protein solubility to obtain distinct 2-D
patterns for each fraction. This is probably due to the low amount of material available and
differences in the ratio of material and solution volumes.
The relatively few differences in the amygdala compared to the cellular system, suggest
also that the cells in the amygdala are probably not in direct contact with the Aβ injected or in
contact with only very small amounts. This would argue in favour of the action of Aβ through
neuronal projections from the hippocampal site of injection to the amygdala which could be
possibly activity or stress dependent. It would be worthwhile tracing the distribution of Aβ after
injection by radioactive labelling of Aβ.
Outlook: We hope that the identification of Aβ mediated changes in both the cellular and
animal system will highlight specific pathways as in the proteomics study of the P301L tau mice,
and that we will be able to further investigate the action of Aβ on these pathways by functional
tests.
4.3 Study of tau insolubility after proteasome inhibition in P301L tau
overexpressing SH-SY5Y cells treated with ß-amyloid
A wide variety of studies have examined the relationship between Aβ and the proteasome.
Aβ has been shown to be degraded by the proteasome (Lopez Salon et al., 2003) but also to
inhibit proteasome activity (Gregori et al., 1995; Song et al., 2003). Furthermore the proteasome
activity was found to be impaired in AD patient brains (Keller et al., 2000). Aβ causes the up-
regulation of mRNA of several components of the ubiquitin proteasome system in cortical
neurones in culture (Song et al., 2003). In particular, they found an induction of E2-25K/Hip-2
with Aβ which they correlated with the inhibition of the proteasome activity. Other studies have
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demonstrated that in vitro, Aβ can directly bind to the proteasome and inhibit its chymotrypsin-
like activity. On the other hand, tau protein has been shown to be degraded by the proteasome
(David et al., 2002) and tau inclusions in oligodendroglial cells are stabilised through the
inhibition of the proteasome (Goldbaum et al., 2003).
Considering the precedent evidence, we speculated that the general inhibition of the
proteasome by MG132 in P301L tau overexpressing neuroblastoma cells and treatment with Aβ
would increase levels of insoluble tau protein. In addition we extrapolated that proteasome
inhibition without Aβ should also cause an increase in insoluble tau. The 20S proteasome
possesses three peptidase activities, cleaving substrates after large hydrophobic, basic or acidic
residues, designated as chymotrypsin-like, trypsin-like, and peptidylglutamyl-peptide hydrolysing
(PGPH) activities, respectively (Orlowski, 1990). We also used in this study, two other
proteasome inhibitors, lactacystin and epoxomicin. Both inhibitors affect all three activities of the
proteasome but inhibit most potently the chymotrypsin-like activity, although epoxomicin acts
with greater specificity than lactacystin (Kim et al., 1999) (Vigouroux et al., 2003) (Fenteany et
al., 1995) (Meng et al., 1999). Aβ has been demonstrated to selectively inhibit the chymotrypsin-
like activity of the proteasome, although not through a direct binding to the catalytic site (Gregori
et al., 1995; Gregori et al., 1997). This study was carried out in vitro therefore it is unclear
whether exposing cells to extracellular Aβ would result in the same specificity of proteasome
activity inhibition, supposing that the cells can internalise small quantities of Aβ. However we
postulated that inhibiting the same proteasome peptidase activity as Aβ, would increase the
potential effects of Aβ on the cellular system. We used low concentrations of both epoxomicin
and lactacystin to avoid inhibiting the other two peptidases activities. As the degradation of tau
protein is unaffected by inhibition of the chymotrypsin-like activity (Cardozo and Michaud,
2002), we speculated that Aβ might cause an increase in tau insolubility through the generation of
specific toxic products from the impaired proteasome degradation process. Furthermore we
hypothesised that inhibiting specifically the chymotrypsin-like activity without Aβ, may
reproduce the effects of Aβ. The whole experiment was carried out on differentiated
neuroblastoma cells as all three proteasome inhibitors inhibit the cell cycle and cause apoptosis,
and we used very low concentrations of all inhibitors compared to other studies. Unfortunately
we observe a significant variability in levels of insoluble tau detected after sequential extraction.
This variability allowed us only to distinguish an “all or nothing” effect on tau insolubility as
seen with Aβ but not to evaluate lesser effects due to the different proteasome inhibitors used.
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However we can conclude that all three inhibitors do not have major effects on Aβ mediated tau
insolubility.
4.4 Study of tau phosphorylation in P301L tau mouse brains
Our group has observed a specific phosphorylation state of soluble tau in P301L tau brains
(Gotz et al., 2001a). The purpose of this study was to identify all the phosphorylation epitopes in
the tau protein in our mouse model. We aimed to identify these phosphorylation sites without
specific antibodies, in order to locate potential new tau phosphorylations. As tau phosphorylation
has a role in determining the binding of tau to microtubules and potentially the propensity of tau
to form fibrils, our objective was to investigate by MS, tau phosphorylation specifically in
soluble AD type tau and not NFT tau (Alonso et al., 2001). Köpke et al. (Kopke et al., 1993) have
published a method to specifically separate AD phosphorylated tau (AD-P tau) from soluble
normal cytosolic tau and NFT tau. This method uses a series of centrifugation steps and
solubilises the AD-P tau in 8 M urea. Finally AD-P tau is separated from non-
hyperphosphorylated AD tau by phosphocellulose chromatography. We carried out the whole
extraction with brains from old P301L tau mice, but we could not detect the presence of tau by
Western blotting in any of the fractions eluted out of the phosphocellulose column. This is
probably caused by too low quantities of AD type tau in the mouse brains as compared to the AD
patient brains used in the original extraction. Thereafter we stopped our extraction before the
chromatography step. First we looked at the 200,000 x g pellet extracted in urea on 2-D gels. The
Western blot of this 2-D show numerous tau species suggesting several sites of phosphorylation.
Unfortunately the pattern on 2-D gels after Silver staining demonstrated a wide variety of other
proteins are present in this fraction and we could only identify one spot as tau. Centrifugation of
the urea soluble fraction to remove more contaminants did not significantly improve the
background.
We can conclude that this method is not adapted to extracting AD-P tau from our mouse
model in the present form and we suggest that it would be worthwhile carrying out an
immunoprecipitation of tau from the urea soluble fraction to enrich AD-tau in order to detect
these on 2-D gels without Western blotting.
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4.5 PipOFF system
The PipOFF system established by Fussenegger et al. (Fussenegger et al., 2000) was tested
in a variety of mammalian cells (CHO-K1, BHK-21, HeLa). In order to assess whether our
constructs were adapted for expression in the mouse system, we demonstrated with success the
expression and inhibition of YFP expression using the PipOFF system in mouse fibroblasts.
However transactivation of YFP expression or another reporter gene such as GFP and LacZ, was
not obtained in transgenic mice having integrated both the PIT construct and the construct
containing PPIR8 controlling the reporter gene. We modified out initial constructs by changing
the promoter controlling PIT expression to the stronger promoter CMV/β-actin and also
modifying the reporter gene, but we still did not observe the expression of the reporter gene
through transactivation with PIT. When generating double transgenic mice through co-injection
of both PIT and reporter constructs and single transgenic mice with only the CMV/β-actin-PIT
construct, we observed very few positive founders and none after single injection of CMV/β-
actin-PIT. On the contrary, generation rates of PPIR8-YFP or PPIR8-GFP founders were normal.
Therefore we can conclude that there is most probably an insertion problem of the PIT construct
into the mouse genome. We could not detect the expression of the reporter in any of the double
transgenics that we produced. However PIT was possibly present in the only double positive
EF1α -PIT and PPIR8-YFP transgenic mouse that transmitted the constructs to her offspring.
Therefore it is difficult to conclude whether the PipOFF system in itself does not work in the
mouse model or whether the lack of reporter expression is due to the absence of PIT
transcription. It would be interesting to carry out an RT-PCR for PIT in the double positive
transgenic lines to establish if the PIT gene is being transcribed into mRNA but not translated
into protein.
In conclusion, our study shows that the PipOFF system in its present form is not adapted to
function in the mouse model. Prof. Fussenegger’s group has since produced several other
transgene regulatory expression systems such as macrolide-based transgene control and gas-
inducible transgene expression systems (Weber et al., 2002) (Weber et al., 2004). These systems
have been shown to work in the mouse when implanting CHO cells containing the system,
intraperitoneally. It would be interesting to see whether transgenic mice can be generated with
these new systems and whether these systems would be functional.
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ABBREVIATIONS
aa: amino acid
Aβ: beta-amyloid peptide
Aβ1-42: beta-amyloid peptide 1-42
Aβ42-1: reverse beta-amyloid peptide 42-1
ACN: acetonitrile
AD: Alzheimer's disease
AD-P tau: AD hyperphosphorylated tau
APP: amyloid precursor protein
APS: ammonium persulfate
CBD: corticobasal degeneration
DBQ: n-decylubiquinone
ddH2O: double deionised water
DMEM: Dulbecco’s modified Eagle’s medium
DRP-2: dihydropyrimidinase related protein 2
DTT: dithiothreitol
ESI: electrospray ionisation
FA: formic acid
FAD: familial form of AD
FCCP: carbonyl-cyanide-p-trifluoro-methoxy-phenylhydrazone
FTD: frontotemporal dementia
FTDP-17: frontotemporal dementia with parkinsonism linked to chromosome 17
GAPDH: glyceraldehyde-3-phosphate dehydrogenase
GFAP: glial fibrillary acidic protein
GFP: green fluorescent protein
GPx: glutathione peroxidase
GR: glutathione reducatase
GRB2: growth factor receptor-bound protein 2
γ-SNAP: γ-soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein
GST: glutathione S-transferase
HAR: hexaammineruthenium(III)-chloride
HS: horse serum
IEF: isoelectrical focusing
IPG: immobilised pH gradients
LC: liquid chromatography
MALDI-TOF: matrix assisted laser desorption ionisation time of flight
MAP: microtubule associated protein
MDA: malondialdehyde
MRI: magnetic resonance imaging
MS: mass spectrometry
MudPIT: multidimensional protein identification technology
MW: molecular weight
NFT: neurofibrillary tangles
PCR: polymerase chain reaction
PDGF: platelet-derived growth factor
PET: Positron emission tomography
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PFA: paraformaldehyde
PHF: paired helical filaments
PHGPx: phospholipid hydroperoxide glutathione peroxidase
PI: pristinamycin
pI: isoelectrical point
PIT: pristinamycin-inhibited transactivator
PPIR: pristinamycin-responsive promoter
PMF: peptide mass fingerprint
PrP: prion protein
PS1: presenilin 1
PSP: progressive supranuclear palsy
ptr: pristinamycin resistance determinant
ROS: reactive oxygen species
RT: room temperature
SB: caprylyl sulfobetaine
SDS: sodium dodecyl sulfate
SILAC: isotope labeling with amino acids in cell culture
SNPs: single nucleotide polymorphisms
SOD: superoxide dismutase
TBP: tributylphosphine
2-D: two-dimensional
2-DE: two-dimensional electrophoresis
TFA: trifluoroacetic acid
TPI: triosephosphate isomerase
Vh: volts x hours
WT: wild-type
YFP: yellow fluorescent protein
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